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DEFINING THE MOLECULAR NETWORKS NECESSARY FOR THYMUS FATE AND
ORGANOGENESIS
Kaitlin Alyssa Gutierrez Reeh, Ph.D. Candidate
Supervisory Professor: Ellen R. Richie, Ph.D.

The thymus and parathyroid (PT) glands originate from endodermal progenitors in the
bilateral third pharyngeal pouches (3rd pps). By E11.5 during mouse development, cells
committed to the thymus lineage express Foxn1 whereas PT-fated cells express Gcm2.
While these transcription factors are required for organ-specific differentiation, the exact
molecular mechanisms that specify endodermal progenitors to either the thymus or
parathyroid lineage are not well defined. Tbx1 is initially expressed throughout the 3rd pp
endoderm, as it is required for segmentation of the pharyngeal apparatus, but is
downregulated in the thymus-fated domain by E10.5. Despite the widely held notion that
Tbx1 is required for thymus organogenesis, we have shown that ectopic expression of Tbx1
in thymic epithelial cells (TECs) suppresses FOXN1, inhibits TEC proliferation and arrests
TEC differentiation, suggesting Tbx1 must be tightly regulated in the 3rd pp endoderm for
proper thymus organogenesis to occur. Members of the miR-17-92 cluster downregulate
Tbx1 in cardiac progenitor cells to permit cardiomyocyte differentiation, and we
demonstrated that members of this cluster are expressed in the 3rd pp endoderm and
mesenchyme. We find that global or TEC-specific deletion of miR-17-92 enhances TBX1
expression and reduces FOXN1 in the 3rd pp. Furthermore, global deletion of miR-17-92
results in an ectopic, hypoplastic thymus lobe, while deletion in TECs results in TBX1+
progenitor cells that persist in the fetal thymus. In contrast, overexpression of miR-17-92 in
TECs results in downregulation of TBX1 in the dorsal 3rd pp and surrounding mesenchyme.
Therefore, these data suggest that miR-17-92 plays an essential role in thymus
development by regulating Tbx1 expression in the 3rd pp.
vii

Additionally, previous work from our lab has shown that a genetic deficiency in neural
crest cells (NCCs) expands thymus fate in the 3rd pp. We show that NCCs mediate this
effect in part by promoting TBX1 expression in the dorsal 3rd pp. Finally, we present
evidence consistent with the dual hypothesis that Fgf8 expression in the ventral 3rd pp
promotes thymus fate by restricting TBX1. Based on these results, we generated a working
model describing the signaling networks that contribute to thymus fate and 3rd pp patterning.
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CHAPTER 1: Introduction
T cells develop in the thymus where multiple stromal cell types form a unique
microenvironment that is indispensable for thymocyte maturation. Thymic epithelial cells
(TECs) are the major component of the stromal network and provide growth, differentiation
and survival signals to thymocytes throughout their differentiation program (1). TECs also
present self-peptides that are required to generate naïve T cells that express a selfrestricted, yet self-tolerant T cell receptor (TCR) repertoire. T cells that emigrate from the
thymus and join the peripheral T cell pool are referred to as naïve T cells, and a constant
supply is required to maintain a highly diverse TCR repertoire. Diversity of the TCR is
essential for generating effective T cell-mediated immune responses against a broad
spectrum of antigens, including pathogens and neoplastic cells. The number of T cells that
emigrate from the thymus directly correlates with thymus size and depends on a functional
TEC network (2-4). Naïve T cell production is at its peak in young individuals, when the
thymus is at its largest. During aging or as a result of stress (i.e. cytoablative therapy), the
thymus involutes largely due to degeneration and disorganization of the TEC compartment.
The resulting decline in naïve T cell output leads to a homeostatic expansion of memory T
cells in the peripheral lymphoid organs. In addition, decreased numbers of naïve T cells
from the involuted thymus result in restricted TCR diversity, which severely compromises the
ability to respond to newly encountered antigens. Consequently, thymus involution is
thought to impair the development of protective immune responses after vaccination and
increase susceptibility to new infectious diseases and cancer. In addition, failure to restore
thymus function and T cell output is an independent predictor of infection and mortality in
allogeneic stem cell transplant recipients (5). Thus, preventing thymus involution and
sustaining T cell output would greatly improve human health. There is great interest in
identifying effective therapeutic strategies to regenerate the involuted thymus. While several
approaches, such as sex steroid ablation (SSA), have been shown to partially restore TEC
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cellularity and thymopoiesis, these effects are transient and functional defects were
observed in the TEC compartment (6-8). These results suggest that regeneration of a fully
functional TEC microenvironment may require activation of specific molecular pathways that
drive the differentiation of TEC progenitors during ontogeny. Therefore, this project is
focused on identifying the genetic pathways necessary to specify endodermal progenitors to
a TEC fate and maintain TEC differentiation in an effort to devise rational therapeutic
approaches for thymus regeneration or preservation.

Thymocyte Maturation is Dependent on TEC Derived Signals
The thymus is composed of thymocytes (developing T cells) and stromal cells, with
thymocytes accounting for greater than 97% of total thymus cellularity. The heterogeneous
thymic stromal compartment is composed of TECs, dendritic cells (DCs), endothelial cells,
macrophages, fibroblasts and B cells. In addition, the thymic stroma is organized into
distinct regions that support different stages of thymopoiesis. These regions consist of
phenotypically and functionally distinct stromal cells, which are found in the cortex, medulla,
subcapsular region and at the cortico-medullary junction (CMJ).
Early in thymus ontogeny, prior to the development of mature medullary and cortical
thymic microenvironments, TEC-derived signals are necessary to support fetal
thymopoiesis. The ventral domain of the 3rd pp endoderm expresses the chemokine CCL25
and the dorsal endoderm expresses CCL21 to attract thymus seeding progenitors (TSPs) to
the 3rd pp as early as E11.5 (9-11). TSPs upregulate the chemokine receptors, CCR7 and
CCR9, and follow a chemotactic gradient to the thymic rudiment (reviewed in (10)). By
E11.5, IL-7 is expressed in the ventral, thymus-fated domain of the 3rd pp and its expression
promotes the survival, expansion and differentiation of TSPs that migrate into the thymic
epithelial microenvironment (12).
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In the adult, TSPs migrate from the bone marrow and enter the thymus through
vasculature at the CMJ. As these TSPs commit to the thymocyte lineage and subsequently
differentiate into functional T cells, they migrate throughout the thymus into different
microenvironments (Fig.1). Early thymocyte progenitors in the thymus parenchyma are CD4
and CD8 double negative (DN) cells. DN thymocytes are a heterogeneous population that
can be further subdivided into four developmental stages based on the expression of CD44,
c-kit and CD25. DN1 cells (CD44+c-Kit+CD25-) are not committed to the T cell lineage and
can generate αβ T cells, γδ T cells, B cells, DCs and macrophages (reviewed in (13)).
Engagement of the Notch 1 receptor on DN1 thymocytes by delta-like ligand 4 (DLL4)
expressed by cortical thymic epithelial cells (cTECs) generates one of the essential signals
required for T cell lineage commitment (14). In the absence of DLL4, thymocyte
development is arrested at the early DN1 stage (15). Notch signaling promotes the
activation of transcription factors (Gata3, Hes1, Tcf7) which are necessary for T-lineage
restriction and continued thymocyte maturation (reviewed in (14)). Recombination activating
gene 1 (RAG1) and RAG2 are expressed by late DN2 (CD44+c-Kit+CD25+) thymocytes and
are required for TCR-β, TCR-γ and TCR-δ gene rearrangement (16, 17). Thymocytes
upregulate the IL-7R during the DN2 stage, as IL-7 signaling is necessary to sustain the
DN2 thymocyte population as these cells progress to the DN3 stage (18). DN3 thymocytes
migrate into the subcapsular region of the thymus and are CD44-c-Kit-CD25+. TEC-derived
Notch signaling is essential for the survival of DN3 thymocytes and progression beyond the
β-selection checkpoint (19, 20). β-selection ensures that DN3 thymocytes successfully
rearrange a TCRβ chain and that it is co-expressed with an invariant pre-TCRα and CD3
polypeptides, forming the pre-TCR complex (reviewed in (14)). Therefore, those thymocytes
that are unable to produce a pre-TCR at DN3 undergo apoptosis because they are unable to
receive survival signals via the pre-TCR and Notch1. However, those DN3 thymocytes that
are signaled via the pre-TCR and Notch, pass through the β-selection checkpoint,
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Figure 1. Thymocyte migration and maturation within the thymus.
The cortiomedullary junction (CMJ) is denoted by a dashed line and a solid line
represents the subcapsule. Thymocytes maturing from double negative (DN) 1-DN4 in the
cortex are purple and single positive (SP) thymocytes in the medulla are orange. Thymic
epithelial cells (TECs) are star shaped with dark orange medullary TECs (mTECs) and dark
purple cortical TECs (cTECs). Thymus seeding progenitors (TSPs) migrate from the adult
bone marrow and enter the thymus through vasculature at the CMJ. Once in the thymus,
TSPs commit to the thymocyte lineage and differentiate. These early thymocyte progenitors
are CD4 and CD8 DN cells and differentiate through four DN stages based on their
expression of c-kit, CD44 and CD25 to become DP for both CD4 and CD8. DP thymocytes
that form αβTCRs capable of recognizing self-peptide in the context of self-MHC are
positively selected in the cortex, downregulate either CD4 or CD8 to become SP thymocytes
and migrate into the medulla. Once in the medulla, SP thymocytes undergo negative
selection to ensure that autoreactive T cells do not circulate throughout the periphery.
Those thymocytes that pass negative selection exit the thymus at the CMJ and enter the
periphery as self-restrictive, yet self-tolerant CD4 or CD8 SP T cells.
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Figure 1. Thymocyte migration and maturation within the thymus.
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downregulate CD25 and become DN4 (CD44-c-Kit-CD25- ) thymocytes that are committed to
the αβ as opposed to γδ T cell lineage. DN4 thymocytes undergo a proliferative burst (eight
to nine cell divisions) and upregulate both CD4 and CD8 to become double positive (DP)
thymocytes which constitute ~85% of total thymocytes (21, 22). TCRα gene rearrangement
is initiated at the DP stage. TCRα and TCRβ polypeptides form TCRαβ heterodimers that
along with non-covalently linked CD3 polypeptides are expressed at low levels on DP
thymocytes.
Positive selection tests the ability of newly formed αβTCRs on DP thymocytes to
recognize self-peptide in the context of self-MHC molecules (reviewed in (23) and (24)).
The majority of DP thymocytes fail positive selection either because they do not express an
αβTCR, or the expressed αβTCR does not recognize self peptide-MHC complexes with low
affinity. In either case, these cells are not signaled to survive and undergo apoptosis (death
by neglect). Only thymocytes that express a TCR capable of recognizing self peptide-MHC
presented by cTECs are rescued from programmed cell death. In order to test the affinity of
TCRs on DP thymocytes, cTECs present self-peptides in the context of MHC class 1 (MHCI)
or MHC class II (MHCII) molecules. Cortical TECs have unique proteolytic pathways for
generating peptides to be presented by MHC. Peptides presented in the context of MHCI
are processed by the thymoproteosome, which contains a unique catalytic subunit
exclusively found in cTECs, called β5t (25). Mice lacking β5t have a defect in positive
selection of MHCI restricted CD8+ thymocytes (25). Self-peptides are also presented in the
context of MHCII molecules expressed on cTECs. In contrast to other antigen presenting
cells (APCs), cTECs have the ability to endogenously process peptides using a process
called macroautophagy, which is dependent upon lysosomal and serine proteases
(reviewed in (23)). Deficiency in macroautophagy or in cathespsin L impairs positive
selection of CD4+ T cells (reviewed in (23)). The expression of unique peptide generating
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machinery by cTECs is consistent with the notion that cTECs play an indispensable role in
presenting a diverse and distinct set of peptides to positively select self-restricted DP
thymocytes. After being positively selected, DP thymocytes are signaled to downregulate
either CD4 or CD8 to become SP thymocytes that are restricted to MHCII or MHCI,
respectively (reviewed in (24)). In addition, single positive (SP) thymocytes upregulate
chemokine receptors such as CCR7 in response to chemokines (CCL19, CCL21) produced
by TECs, which facilitates their migration into the medulla (26).
Central tolerance is established in the medulla where many self-reactive T cell
clones are deleted during the process of negative selection. Medullary thymic epithelial
cells (mTECs) have the unique ability to present a vast array of self-antigens termed tissuerestricted antigens (TRAs) that are otherwise expressed only in peripheral tissues. SP
thymocytes that express TCRs that recognize self-antigen in the context of MHC with high
affinity undergo apoptosis, thus preventing most autoreactive T cells from entering the
periphery. While mTECs express a wide array of TRAs, the frequency at which each TRA is
expressed is very low, reducing the likelihood of thymocyte-APC interactions (27, 28).
Therefore, thymocytes must migrate quickly and efficiently throughout the medullary region
of the thymus to maximize the frequency at which they encounter APC presentation of TRA
(29).
The ability of mTECs to express a subset of TRAs is mediated by the transcription
factor autoimmune regulator (AIRE) (30). AIRE binds to histone 3 on the lysine 4 residue
(H3K4) and interacts with other transcriptional regulators to promote activation of “silent”
genes that are otherwise lineage restricted (31, 32). Mice and humans deficient in Aire fail
to eliminate autoreactive T cells during thymopoiesis and develop autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (30, 33). Presentation of
TRAs to developing thymocytes in the medulla is not only restricted to the mTEC stromal
population. Dendritic cells are also capable of presenting self-antigen in the context of MHC
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to thymocytes, despite the fact that they are Aire-/-. This is because mTECs have the unique
ability to transfer self-antigen to DCs (34, 35).
Negative selection ensures that most cytotoxic CD8 and CD4 helper T cells do not
bind to, and recognize self-peptide with high affinity, generating an autoimmune reaction.
However, mTEC-mediated testing of TCR affinity is also important for regulatory T cell (TReg)
development. TReg cells are a subset of T cells that function to negatively regulate T cell
immune responses that occur in response to autoimmune disorders, chronic infection or
allergic reactions (36). Regulatory T cells are generated when SP thymocytes recognize
self-peptide with high affinity, but not high enough to induce apoptosis (23). Therefore, the
medulla not only provides an environment for the elimination of autoreactive T cells, but also
promotes the maturation of T cells necessary for dampening peripheral immune responses
and preventing self-reactivity.
SP thymocytes that survive both positive and negative selection emigrate from the
thymus and once in the periphery, naïve CD4+ and CD8+ T cells circulate throughout the
blood and lymphatic system. After encountering APCs that present foreign peptide-MHC
complexes in secondary lymphoid organs, peripheral T cells undergo clonal expansion and
differentiate into either helper CD4+ or cytotoxic CD8+ T cells to mediate their effector
functions. However, for this to occur, cTECs and mTECs are required throughout the
thymocyte maturation process to generate self-tolerant, yet self-restrictive T cells.

Thymocyte Derived Signals are Important for TEC Maturation
The progression of thymocytes from early thymic progenitors (ETPs) to functionally
competent CD4+ or CD8+ T cells is a non-cell autonomous process that depends on
appropriate signals from TECs. Conversely, several studies have shown that thymocytes
provide indispensable signals for TEC survival and differentiation (37-39). Mouse models
that display early blocks in thymocyte maturation have been used to study the contribution
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of thymocyte-derived signals to cTEC and mTEC maturation (40, 41). RAG2/common γc deficient and hCDε transgenic mice have a very early block in thymocyte maturation,
specifically at the DN1 stage (40, 41). Consequently, there is a failure in cTEC
differentiation and these mice lack a three-dimensional TEC network. However, if
thymocyte maturation progresses beyond DN1 to DN3, as in the RAG2-/- model, these mice
form three-dimensional cortical regions as well as medullary islets that fail to differentiate.
These models clearly demonstrate that developing thymocytes provide signals that are
required to generate mature cTECs and mTECs in the postnatal thymus. However, we have
shown that the initial stages of TEC differentiation in the fetal thymus occur independently of
thymocyte-derived signals. Ikaros is a transcription factor that is required for commitment to
the lymphoid lineage and mice null for this transcription factor have a significant delay in B
and T cell development due to a deficiency of thymus seeding hematopoietic progenitors at
early fetal stages (42). When thymus organogenesis was studied in Ikaros-/- mice, Klug et
al. found that the fetal thymus was capable of organizing into cortical and medullary regions
at E15.5, despite the fact that there was a delay in thymocyte development (43). These
data demonstrate that initial thymus organogenesis is independent of lymphoid-derived
signals (41, 44).

Involution
The thymus undergoes gradual and progressive involution during aging. Acute
thymus involution occurs as a result of cytoablative therapy, severe viral infection and
pregnancy (45). Although the exact mechanisms that govern thymus involution are
unknown, this process is in large part due to atrophy of the TEC compartment (7). As the
thymus involutes, thymopoiesis declines. The resulting decrease in naïve T cell output
restricts TCR diversity in the peripheral T cell pool, which in turn compromises the immune
system’s ability to respond to newly encountered antigens. Thus, thymus involution is

9

associated with increased susceptibility to infectious disease and cancer, poor responses to
vaccines as well as increased autoimmunity.
Since thymus involution negatively impacts overall health, there has been
considerable interest in restoring the involuted thymus to a functional state that supports
robust thymopoiesis. SSA is a well-characterized approach that restores cellularity and
organization of the involuted thymus in aging humans and mice. However, this effect is
transient, as old, regenerated thymi may not be functionally competent compared to a young
thymus (6). Specifically, regenerated thymi fail to form discrete medullary regions capable of
expressing a full complement of TRAs (6).
Other approaches have been taken to regenerate the involuted thymus. For
example, exogenous administration of keratinocyte growth factor (KGF) and IL-7 to old mice
has been shown to increase TEC cellularity and thymopoiesis. During thymopoiesis, IL-7 is
important for thymocyte survival and maturation, and IL-7 as well as IL-7 receptor (IL-7R)
knockout mice exhibit significantly reduced total thymus cellularity (46, 47). Treatment with
exogenous IL-7 results in an expansion of the early DN subsets and increased thymocyte
cellularity in some, but not all studies (reviewed in (7)). Both KGF (also known as FGF7)
production by developing thymocytes and FGFR2IIIb (FGF7 receptor) expression by TECs
is required for thymocyte differentiation (48). Administration of KGF after cytoablative
therapy results in increased total thymus cellularity as well as an expansion in the peripheral
T cell pool (reviewed in (7)). However, similar to SSA, IL-7 or KGF administration only
transiently restores thymus cellularity.
It is clear that the methods being used to rejuvenate the aged thymus are not
restoring the full developmental program within the TEC progenitor population. Thus, a
more promising approach would be to recapitulate the signaling pathways active during
embryonic development to ensure proper functionality of TECs. However, in order to

10

generate TECs from fetal progenitors, it is important to understand the pathways that
regulate their development during ontogeny.

Overview of Thymus Organogenesis
The pharyngeal region of the developing embryo is segmented into a series of
bilateral arches that develop in an anterior to posterior manner. The pharyngeal arches
(PAs) are comprised of pharyngeal pouches (pps) (endoderm) and pharyngeal clefts
(ectoderm) separated by mesoderm-derived mesenchyme (Fig.2). The single layer
endoderm of the first pp gives rise to the auditory tube, the second pp will develop into the
palatine tonsil, and the fourth pp develops into the ultimobrachial body. Additionally, each
third pp generates a shared primordium which gives rise to one thymus lobe and one PT
gland (49).
To conclusively determine if the thymus originates from endodermal and/or
ectodermal contributions, a series of experiments were performed in which E8.5-E9.0 3rd pp
endoderm and ectoderm were transplanted under the kidney capsule of a Foxn1nu/nu (nude)
mouse (50). This study found that 3rd pp endoderm, not ectoderm, was capable of giving
rise to a thymus that could organize into cortical and medullary regions as well as support
the maturation of functionally competent T cells. In addition, this study suggests that cells
comprising the 3rd pp endoderm have already committed to either a thymus or PT fate very
early in ontogeny.
Thymus fate is specified in the ventral region of the 3rd pp as early as E9.5-E10.5
(50), in a process that relies on endodermal-mesenchymal crosstalk (51). While the thymusand PT-specific domains of the 3rd pp are not morphologically distinguishable at E11.5,
organ specification is revealed by expression of the transcription factors Forkhead box
protein N1 (Foxn1) in the ventral, thymus-fated domain and glial cells missing-2 (Gcm2) in
the dorsal, PT-fated domain (52, 53) (Fig.3B). Therefore, these markers are useful to detect
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Figure 2. Pharyngeal morphology.
The pharyngeal arches (PAs) are divided into three germ layers; endoderm (green),
ectoderm (blue) and mesenchyme (yellow). The endodermal and ectodermal layers
separate the pharyngeal pouches (pps) and pharyngeal clefts. Mesoderm- and neural crestderived mesenchyme form the core of the PAs. The thymus and parathyroid originate from
the 3rd pp endoderm.
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Figure 3. Thymus organogenesis.
(A) Coronal representation of the pharyngeal arches at E9.5. The thymus and
parathyroid originate from the bilateral 3rd pp endoderm. (B) Sagittal representation of 3rd pp
patterning in the E11.5 endoderm. The ventral domain of the 3rd pp gives rise to the thymus
(green) and the dorsal domain gives rise to parathyroid (red). Although not morphologically
distinguishable, cells fated to become thymus express Foxn1 and those cells fated to
become the parathyroid express Gcm2. Neural crest cells are represented in blue. (C) By
E12.5, the thymus and parathyroid detach from the pharynx and begin to separate form one
another. (D) The thymus and parathyroid migrate to their final locations. The thymus is
located anterior to the heart and the parathyroid is adjacent to the thyroid.
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Figure 3. Thymus organogenesis.
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early patterning of the 3rd pp. Foxn1 is required for the proliferation and differentiation of
TECs and expression of Gcm2 is necessary for the survival and development of the PT
gland (54). Since neither transcription factor is required to establish organ fate, other
molecular signaling networks are necessary to initiate cell fate acquisition.
Morphological identification of thymic lobes and PT glands is apparent beginning at
E12.5 as the thymus and PT separate from the pharynx and one another, and begin to
migrate to their final locations (Fig.3C,D). The thymus migrates ventrally and medially until it
is just anterior to the heart and the PT migrates caudally into the neck to its final location
next to the thyroid gland (Fig.3D). By E12.5-E13.5, cortical and proto-medullary regions are
apparent in the thymic primordium and MHCII expression on TECs is initiated (55-57).
In order to identify TEC subsets, cytokeratins can be used to distinguish cortical from
medullary TECs. By E12.5, the initial emergence of cortical and medullary thymic epithelial
cell lineages is first observed and can be distinguished from one another by the expression
of cytokeratin 8 (K8) and K5, respectively. TECs that are K5+ tend to localize to the middle
of the lobe (medulla) and express lower levels of K8, with K5-K8+ cells expressed towards
the outer region of the lobe (cortex) (43, 55). As development progresses, progenitor-like
cells that co-express K5 and K8, downregulate either K5 or K8, suggesting that these cells
are committing further to either an mTEC or cTEC lineage (43, 55). By E17.5, the fetal
thymus consists of distinct cortical and medullary regions that are K8+K5- and K8-K5+,
respectively, with only the cells at the CMJ being K5+K8+.

Neural Crest and Mesoderm-derived Mesenchyme Contribute to Thymus
Organogenesis
Neural crest cells (NCCs) are a multipotent population of stem/progenitor cells that
delaminate from the dorsal neural tube and migrate ventrally in discrete streams. NCCs
give rise to numerous derivatives including, endocrine, mesenchymal and adipose cells, as
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well as neurons, cartilage and skin (58). NCCs surround the 3rd pp by E10 and form the
mesenchymal capsule that condenses around the developing thymic primordium (59, 60).
Studies have shown that thymus fate is established prior to NCCs reaching the pouch and
that NC depletion results in thymus aplasia or hypoplasia (61).
NCCs play an indispensible role in various processes during thymus organogenesis.
Specifically, NCCs contribute to pouch patterning, supply essential growth factors that
support the proliferation and outgrowth of TECs as well as contribute to thymus vasculature
(62-65). This multipotent population of cells is capable of differentiating into pericytes and
contributes to the thymus vasculature at E14.5 (66). Pericytes function to maintain vessel
integrity and dysregulation of NC-epithelial interactions results in a delay in thymus
vascularization (66). In addition, NCCs are required for the timely separation of the thymus
and PT gland as well as the proper migration of the thymic primordium (63).
The transcription factor, Pax3 is required for the survival, proliferation and
differentiation of NCCs (67-69). A homozygous point mutation in the Pax3 gene (Splotch),
results in embryonic lethality by E13.5 due to numerous developmental defects (67, 68). In
addition, these mice are characterized as athymic, suggesting a role for NCCs in thymus
development. However, Griffith et al. found that Pax3Sp/Sp mutants were not athymic, but
rather had severely ectopic, hyperplastic thymic lobes when compared to control littermates
(70). Furthermore, when 3rd pp patterning was analyzed at E11.5, they found an expansion
in the Foxn1 domain as well as a significant reduction in Gcm2 expression (70). This
suggests that NCCs are not only important in thymus morphogenesis, but may play a role in
patterning the 3rd pp and influence cell fate decisions.
Although not well studied, mesoderm derived mesenchyme in the pharyngeal arches
also plays an important role in thymus organogenesis. The T-box transcription factor, Tbx1,
is expressed by mesodermally-derived mesenchymal cells, and loss of Tbx1 results in a
complete failure in the segmentation of the pharyngeal apparatus (71). Consequently, the
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3rd pp never forms, thus abrogating thymus development. Furthermore, the mesodermal
expression of Tbx1 is required for the patterning and proliferation of the pharyngeal
endoderm (71), thus providing further evidence that mesoderm-derived mesenchyme
provides additional, unknown factors that are necessary for proper development of the 3rd
pp.

Growth Factors and Morphogens Play Essential Roles in Thymus Organogenesis
Fibroblast growth factors
During thymus development, the NCCs supply several fibroblast growth factors
(FGFs) that are important to 3rd pp patterning, proliferation, outgrowth and eventual organspecific migration. At E12.5, the NC mesenchymal capsule that surrounds the thymic
primordium expresses Fgf7 and Fgf10, which promote TEC proliferation (72, 73). In
addition, TEC expression of FGF receptor, FgfR2IIIβ, persists in the postnatal thymus, as
does thymocyte expression of Fgf7 and Fgf10 (48, 74, 75). Embryonic deletion of FgfR2IIIβ
on TECs causes a block in TEC proliferation and differentiation, resulting in thymus
hypoplasia and an arrest in thymocyte development (72). Interestingly, the Fgf10 (72), and
not Fgf7 (76), deletion model recapitulates the phenotype observed in FgfR2IIIβ-/- mice,
suggesting that Fgf10 and Fgf7 may function differently during thymus development.
However, their continued expression in the postnatal thymus suggests a role for FGF
signaling in TEC maintenance. Furthermore, exogenous administration of FGF7 is capable
of transiently restoring the involuted thymus (reviewed in (7)), providing additional evidence
that FGF signaling is important in TEC maturation and homeostasis.
Fgf8 is another member of the FGF family that is implicated in embryonic thymus
development. Fgf8 is expressed in the ventral 3rd pp endoderm, but is almost completely
absent from the pouch by E11.5 (77). Mice harboring a hypomorphic Fgf8 allele display
variable thymic phenotypes ranging from thymus aplasia to hypoplasia (78, 79). However,
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these mice die in utero as a result of multiple complications including; aberrant cardiac
development, craniofacial defects and hypoplastic pharyngeal arches (78, 79). The majority
of these phenotypes may be secondary to the PA hypoplasia, suggesting that Fgf8 is
important for proper development of tissues derived from the PAs and NCCs (78).

Bmp and SHH
Morphogens are signaling molecules that act across a concentration gradient to
influence the cell fate and patterning of developing tissues. Bone morphogenic protein 4
(Bmp4) is a member of the TGFβ superfamily and functions to promote thymus development
early in ontogeny. At E10.5, Bmp4 is expressed in the arch mesenchyme, however is
absent from the 3rd pp endoderm until E11.5 (80). At this time, Bmp4 expression is
restricted to the ventral, thymus-fated domain of the pouch endoderm and mesenchyme
(80). Bmp4 expression expands throughout the E12.5 primordium and is expressed in the
adjacent mesenchymal capsule, suggesting Bmp4 is necessary for thymus outgrowth (80).
To define in what capacity BMP4 acts in thymus and PT organogenesis, Gordon et
al. performed a series of experiments in which Bmp4 was deleted from either the 3rd pp
endoderm or surrounding NC-mesenchyme. Pouch patterning was not altered in any of the
mutants, and thymus-PT differentiation and migration were unaltered in mutants that had
Bmp4 deleted from either the NCCs or TECs (81). However, simultaneous deletion of Bmp4
in both the NCCs and TECs resulted in incomplete capsule formation, a significant delay in
organ separation and failure of both organs to migrate to their appropriate locations (81).
Interestingly, both Bmp2 and Bmp4 are required for myocardial differentiation, as deletion
arrests cardiac cells in a progenitor stage (82). Therefore, the mild thymus phenotype
observed when Bmp4 is deleted in the endoderm and NC-derived mesenchyme may be
attributable to the redundant function of Bmp2 in pouch patterning and thymus
organogenesis.
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Inhibition of BMP signaling using an antagonist, results in phenotypes similar to what
is seen in the deletion models. Noggin is a secreted protein that antagonizes BMP signaling
and its expression is restricted to the dorsal domain of the 3rd pp, suggesting it is necessary
to inhibit thymus fate and allow for the establishment of PT fate (83, 84). When a Noggin
transgene regulated by the Foxn1 promoter is ectopically expressed in TECs, the inhibition
of Bmp signaling results in hypoplastic, cystic thymic lobes that fail to migrate (83). This
suggests that BMP signals are necessary for the development and migration of the thymic
lobes.
There is evidence that BMP and FGF signaling networks act in concert to promote
3rd pp patterning and thymus development. Neves et al. demonstrated that sequential BmpFgf signaling in chick is required for Foxn1 and Gcm2 expression in the 3rd and 4th pps.
Mesenchymal production of Bmp4 is required within a 24-hour period for 3rd and 4th pp
endoderm development (85). However, beyond this point expression of Bmp4 from the
mesenchyme was no longer needed to promote thymic epithelial differentiation. Rather,
expression of Fgf10 from the mesenchyme was needed to support late-stage epithelial
differentiation. Neves et al. proposed a model in which a signal from the endoderm is
required to recruit somatopleural mesenchyme to the 3rd and 4th pps to induce a Bmp4Fgf10 signaling cascade that promotes patterning of the pouches into thymus and PT
domains and supports their subsequent differentiation. Interestingly, they hypothesize that
endodermal expression of Fgf8 may be this inductive signal, given its role in early thymus
ontogeny.
Sonic hedgehog (SHH) is another morphogen that is critical for 3rd pp patterning.
SHH is expressed throughout the PAs, but is not detected in proximity to the 3rd pp until
E10.5 when it is located in the endoderm closest to the pharynx (86). At E11.5, Shh
expression extends into the ventral region of the first and second pps, however is no longer
detected in the third or fourth pps (86). The SHH receptor Patched (Ptc1) is more widely
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expressed. Until E11.5, Ptc1 is restricted to the opening of the third and fourth pps and
dorsal mesenchyme, from which point Ptc1 expression expands in the mesenchyme, but
remains absent from the most ventral regions of the 3rd and 4th pps (86).
SHH acts in opposition to BMP and is required for PT development (86). SHHNull
mutants fail to express Gcm2, resulting in aberrant 3rd pp patterning and aparathyroidism
(86). Given that SHH is no longer present in the mesenchyme to oppose BMP signaling,
there is an expansion of BMP4 towards the pharynx (86). Interestingly, the expansion of
Bmp4 in the SHH null mutants is concomitant with an expansion of Foxn1 throughout the 3rd
pp and into the pharynx (86). This suggests that SHH signaling is required for PT
development and in its absence, thymus fate expands throughout the pouch.

Thymic Epithelial Progenitor Cells
It is well established that the fetal thymus contains bipotent progenitors capable of
giving rise to both cortical and medullary TECs (55, 87, 88). Thymic epithelial progenitor
cells (TEPCs) were first characterized in a study using chimeric mice to define the role of the
Foxn1nu (nude) gene in thymus organogenesis (88). Thymus development is arrested at an
early stage in the Foxn1nu/nu model and these mice have a small, highly cystic thymic
rudiment. In the presence of wildtype cells, the nude epithelium is unable to differentiate into
mature TEC subsets, suggesting that the nude gene acts cell autonomously. Furthermore,
in the adult chimeras, a small population of nude cells that failed to express mature TEC
markers (Foxn1, MHCII, MTS10) was able to persist, suggesting that the nude rudiment
contains TECs that are arrested at a primitive differentiation stage (88). Interestingly, these
TECs expressed antigens identified by two monoclonal antibodies, mouse thymic stroma 24
(MTS24) and MTS20. These antigens were also expressed on a rare subset of mTECs in
the adult thymus, further suggesting that these cells might be a progenitor population of
TECs.
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Later studies showed that MTS24 was expressed throughout the 3rd pp endoderm
and the frequency of MTS24+ TECs significantly declines with age and becomes restricted
to the medullary region of the thymus (89). To address whether or not MTS24+ cells were
truly TEC progenitors, these cells were isolated and transplanted into recipient mice. Upon
transplantation, MTS24+ cells were able to differentiate and generate a thymic rudiment
capable of attracting and supporting lymphocyte maturation (55, 89). This supported the
notion that these cells were bipotent progenitors capable of generating cTECs and mTECs.
To further characterize the TEPC, Depreter et al. found that MTS20/24 bound an orphan
protein, placenta expressed transcript (Plet)-1. The expression pattern of Plet-1 is
congruent with MTS20/24 in the 3rd pp and throughout thymus development (90). In
addition, Plet-1 expression is detected in stem-like pancreas and mammary cells (90),
therefore identifying Plet-1 as a novel protein that can be used to detect progenitor
populations.
Additional molecules that are indicative of differentiation status and distinguish
cTECs and mTECs have also been identified. Early in ontogeny, TECs express not only
Plet-1, but also Claudins (Cldns) 3 and 4, CD205 and β5t (90-93). Cldn3/4 expression is
associated with mTECs and CD205 as well as β5t are used to identify cTECs. However, at
early developmental stages, these molecules also identify progenitor populations within the
thymus. In the same study that defined Plet-1 positive cells as bipotent progenitors,
Depreter et al. found that the tight junction proteins, Cldn4 and Cldn7 could also be potential
TEPC markers. Interestingly, Cldn3/4 is expressed in the developing 3rd pp endoderm as
well as by mTECs in the adult thymus (91). In addition, Hamazaki et al. found that Cldn3/4
positive cells eventually give rise to terminally differentiated Aire+ mTECs (91), suggesting
that these molecules identify progeny of the mTEC lineage. Similarly, studies have shown
that CD205 cells and β5t positive cells identify the earliest progenitors of cTEC and mTEC
lineages (91, 92). However, as development continues, their expression becomes restricted
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to the cortical sublineage. Given that Cldn3/4, CD205 and β5t are all expressed as early as
E11.5 and become lineage restricted throughout thymus development, suggests that
bipotent progenitors are capable of expressing both cTEC and mTEC markers early in
development, but are differentially regulated later in organogenesis. These data, as well as
others, have shown evidence suggestive of a progenitor population within the adult thymus
that is capable of generating medullary and cortical lineages (94, 95).
To discern if there is a different population of TEPCs within the adult versus fetal
thymus, recent studies have employed the use of stem cell surface markers and cell culture
to identify a population of self-renewing adult TEPCs that may be phenotypically different
from that of fetal progenitors, but capable of giving rise to differentiated TEC lineages (96,
97). Specifically, MHCIILoSca+ cells isolated from the adult thymus were able to give rise to
terminally differentiated TECs (96, 97). In addition, these and other studies have shown that
adult TEPCs are capable of persisting in the presence of low to negative levels of Foxn1
(96, 98). However, these reports do not agree on whether or not restoration of Foxn1 levels
is necessary for TEC maturation. Therefore, with the identification of a potentially rare
population of adult TEPCs that are capable of giving rise to a functional thymus, further work
needs to be done to define what molecular pathways govern adult TEPC maintenance and if
this stem population is functionally distinct from that of fetal TEPCs.

Transcriptional Regulation of Thymus Organogenesis
Thymus development depends on complex and continuous interactions between
differentiating endoderm, thymocytes, endothelial and mesenchymal cells. Failure in any
component of this multicellular crosstalk can result in a multitude of developmentally
aberrant phenotypes. While the molecular signaling networks that specify 3rd pp cell fate
have yet to be defined, several transcription factors have been identified that are important
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in the early stages of thymus organogenesis. These transcriptional regulators are discussed
below and are summarized in Table 1.

Foxn1
Foxn1 is a key transcription factor that is nonredundant and critical for TEC
differentiation and proliferation. Foxn1 expression is first detected in the 3rd pp at ~E11.25,
and is restricted to the ventral, thymus-fated domain of the endoderm (54). During later
stages of fetal development, Foxn1 is widely expressed by both cTECs and mTECs.
However, the amount and frequency at which TECs express Foxn1 declines with age,
suggesting a correlation between Foxn1 levels and involution. The loss of Foxn1 causes a
reduction in TEC organization and proliferation and indirectly results in a decline in T cell
output (99). Mice that have a hypomorphic Foxn1 allele maintain normal levels of Foxn1
throughout fetal TEC development, but expression is significantly reduced by one week
postnatally (99). Specifically, TECs that express higher levels of Foxn1 (MHCIIHiUEA-1Hi
mTECs) were more sensitive to Foxn1 modulation (99). Given that reduction in Foxn1 is an
early event in thymus involution, this model phenocopies age-related thymus involution, but
at an accelerated rate. The fact that fluctuating levels of Foxn1 can impact TEC maturation
is further supported by the use of a revertible hypomorphic Foxn1 allele. Nowell et. al
demonstrated that while Foxn1 was not required for TEC fate commitment, it is required for
divergence into either cortical or medullary TEC sublineages and that reducing the levels of
Foxn1 alters gene expression, which ultimately, affects the terminal differentiation and
function of TECs (57). Interestingly, the genes that were affected are known regulators of
thymic epithelial commitment and differentiation; such as Pax1, MHCII and Dll4, all of which
were shown to be either directly or indirectly downstream of Foxn1.
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Table 1. Transcriptional regulation of thymus development.
Description of the expression pattern and thymus phenotypes of transcription factors
implicated as regulators of thymus organogenesis.
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Table 1. Transcriptional regulation of thymus development.

Transcription
Factor
Foxn1

Location of Expression

Mutant Phenotype
Small, highly cystic thymic rudiment
that contains undifferentiated,
MTS24+ TEPCs
Complete failure in segmentation of
the pharyngeal endoderm, thymus
never develops
Early block in 3rd pp patterning, delay
in Foxn1 and Gcm2 expression,
thymus aplasia or hypoplasia

Pax1

E11.25-restricted to ventral domain
of 3rd pp
Expressed by TECs
E9.5-throughout 3rd pp endoderm
E10.5-restricted to dorsal domain of
3rd pp
E10.5-throughout 3rd pp endoderm
and surrounding mesenchyme
E11.0-downregulated in 3rd pp
endoderm and surrounding
mesenchyme
E13.5-absent from 3rd pp endoderm
and surrounding mesenchyme
E9.5- 3rd pp endoderm

Pax9

E9.5- 3rd pp endoderm

Eya-1

E10.5-throughout 3rd pp endoderm
and surrounding mesenchyme

Six-1

E10.5-throughout 3rd pp endoderm
and surrounding mesenchyme
E10.0- ventral tip and proximal
dorsal region of the 3rd pp
E11.5- ventral domain of 3rd pp
Expressed by TECs

Thymus hypoplasia and a failure of
thymus-PT separation
rd
3 pp endoderm fails to detach from
the pharynx, failure in pouch
patterning, thymus aplasia
Athymic

Tbx1
Hoxa3

Foxg1

Reduced thymocyte cellularity

Yet to be defiend

Isl1

E9.0- ventral domain of 3rd pp
endoderm
E10.0-ventral domain of 3rd pp
endoderm
Expressed by TECs

Embryonic lethal at E9.5-E10.5

Nkx2-5/6

E9.0- 3rd pp endoderm
E10.0-ventral domain of 3rd pp
endoderm

Aberrant pharyngeal endoderm
development
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Furthermore, upregulation of Foxn1 in the involuted thymus is sufficient to restore the
function of key regulatory genes that promote TEC proliferation and differentiation (100). In
contrast to SSA methods of thymus rejuvenation, this study also showed that the restored
thymus was comparable in both stromal architecture and genetic profile to that of a young
thymus (100). Furthermore, previous studies have also shown that when Foxn1 is
expressed in TEPCs, it promotes the differentiation of both cortical and medullary TEC
lineages (87). Taken together, these experiments demonstrate that small changes in Foxn1
levels can have profound effects on TEC differentiation and function.
Numerous studies have described the indispensible role Foxn1 has throughout
thymus development; beginning from onset of expression in progenitor cells at E11.25, its
maintained expression to ensure TEC differentiation, as well as its decline at the onset of
thymus involution. However, it is evident that Foxn1 is a hallmark of thymus fate, and does
not specify endodermal progenitors to thymus fate. Therefore, additional mechanisms and
key regulatory factors must be required for cell fate decisions.

Hox-Pax-Eya-Six Signaling Network
The Hox, Pax, Eya, Six gene network is highly conserved from Drosophila to
vertebrates. Each gene is expressed, at some point during ontogeny, throughout the 3rd pp,
and mutations in any of these genes results in similar phenotypic abnormalities, including
thymus and PT aplasia or hypoplasia.
Hoxa3, a member of the Homeobox protein family, is expressed by NCCs as they
migrate throughout the PAs (101-103). By E10.5 Hoxa3 is expressed in the endoderm of
the 3rd and 4th pps as well as in the arch mesenchyme surrounding the two pouches (101103). Detailed in situ hybridization (ISH) analysis of Hoxa3 expression revealed that at
E10.5, Hoxa3 is strongly expressed throughout the 3rd PA mesenchyme and endoderm, but
its expression is downregulated in the endoderm and mesenchyme at E11.0 and E12.0,
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respectively, until it is completely absent by E13.5 (104). NCC migration is unaffected in
Hoax3 mutant mice and there is no defect in pp formation (101-103). However, there is an
early block in 3rd pp patterning, which results in an aplastic or hypoplastic thymic phenotype
as well as a hypoplastic PT that fails to migrate (101-103).
A recent study performed experiments to determine the expression pattern and
timing of 3rd pp region-specific markers in Hoxa3 null mutants. Temporal and spatial
expression of thymus- and PT-specific markers revealed that Hoxa3 is required for Gcm2
expression to be maintained beyond E10.5 and its absence causes Tbx1 expression to be
significantly downregulated, although never extinguished in the presumptive PT-fated
domain (104). When thymus-specific markers were analyzed, Foxn1 expression was not
detected until E12.0 (104). Tissue specific deletion of Hoxa3 in the 3rd pp endoderm
resulted in delayed expression of Foxn1 coupled with thymus and PT ectopia and
hypoplasia (104). The thymus and PT phenotype was similar in the NC deletion of Hoxa3,
but there was a failure in organ separation and migration (104). Compound deletion of
Hoxa3 in the endoderm and NCCs phenocopied Hoxa3 null mutants (104). These data
suggest that Hoxa3 contributions to thymus and PT development are tissue specific and
required for proper patterning, organogenesis and morphogenesis.
The Pax1/9, Eya1, Six1/4 signaling network is highly conserved from drosophila to
vertebrates. During embryonic development, each transcription factor is differentially
expressed in the ectoderm, endoderm and/or mesenchyme and mutations in any of the
genes results in a range of thymus phenotypes (103). Specifically, the 3rd pp endoderm fails
to detach from the pharynx in Eya1-/- embryos and Gcm2 and Foxn1, are never expressed in
the endoderm (105). Consequently, the thymus and parathyroid never form in these
mutants. In addition, a mutation in Pax1 results in reduced thymocyte cellularity, while Pax9
mutants have a more severe phenotype, characterized by thymus hypoplasia and a failure
of thymus-PT separation (reviewed in (106)). Interestingly, the thymus and kidneys are
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absent in Six1-/- mice and they exhibit craniofacial abnormalities reminiscent to what is seen
in mice with mutations in the transcription factors Tbx1, Pax1 and Eya1 (107). As described
in all of these mutants, the severe thymus and PT phenotypes may be attributable to the fact
that the 3rd pp was never patterned into distinct thymus and PT domains. However, none of
the transcription factors discussed have been implicated in the establishment of thymus cell
fate.
A comprehensive ISH analysis was performed to identify potential transcriptional
targets that are expressed in the presumptive thymus-fated domain at and prior to E9.5
(108). Interestingly, several of the genes identified are expressed by cardiac progenitor
cells and have a role in cardiac development. These common genes, as identified by the
ISH analysis, are Nkx2-5, Nkx2-6 and Isl1. Expression of Nkx2-5, Nkx2-6 and Isl1 is
required for PE formation and all are expressed within the 3rd pp endoderm as well as have
a role in postnatal TEC development (108-110). Specifically, Nkx2-5 positive cells contribute
to the TEC lineage (110) and Isl1 is expressed in the thymus by late fetal and postnatal
TECs (108).
In the same study, analysis of Foxg1 expression revealed that it is initially expressed
at E10.0 in the most ventral region of the 3rd pp and its expression is maintained in the same
location at later stages, but is also detected in a discrete region of the dorsal domain. Our
work has shown that at E11.5, FOXG1 expression overlaps with, and is independent of,
FOXN1 (111). Similar to Isl1, Foxg1 is expressed in late fetal and adult TECs (108).
Additional studies need to be performed to determine if and how these genes contribute to
fate specification of the 3rd pp.

The Conundrum of Tbx1
The exact role of Tbx1, a T-box transcription factor, during thymus organogenesis
has been contested. Tbx1 is expressed throughout the pharyngeal endoderm and arch
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mesenchyme at E7.5, but is not expressed by NC-derived mesenchyme (112). Deletion or
mutation of Tbx1 results in cardiac outflow defects, thymus and PT hypoplasia as well as
craniofacial abnormalities (113). Furthermore, homozygous deletion of Tbx1 in mouse
models phenocopies the 22q11.2 deletion (DiGeorge) syndrome, with thymus aplasia as a
hallmark, thus implicating it as the gene responsible for DiGeorge syndrome (114-116).
Based on these data, the prevailing thought in the literature is that Tbx1 is required for
thymus organogenesis, as loss or haploinsufficiency of Tbx1 results in thymus aplasia or
hypoplasia. However, conditional over expression of Tbx1 results in cardiac hypertrophy,
outflow tract defects and thymus hypoplasia (117). Therefore, this suggests that Tbx1attribuatble phenotypes may be dose dependent, further complicating the role of Tbx1
during thymus organogenesis.
Importantly, Tbx1 is required for segmentation of the pharyngeal endoderm, as the
pharyngeal apparatus fails to form in Tbx1-/- mice (112, 114, 115, 118, 119). Given that the
loss of Tbx1 abrogates 3rd pouch formation, it is reasonable to hypothesize that the athymic
phenotype observed in DiGeorge syndrome is secondary to the loss of Tbx1, and
attributable to the fact that the 3rd pouch never formed. Furthermore, temporal deletion of
Tbx1 reveals that loss of Tbx1 expression at E8.5 abrogates 3rd pp formation, providing
additional evidence that athymia is the result of a failure in pouch formation (120).
Furthermore, the expression pattern of Tbx1 in the wildtype 3rd pp is interesting in
that it is initially expressed throughout the pouch, but is downregulated by E10.5 in the
ventral, thymus-fated domain and restricted to the dorsal, PT-fated domain (112, 121, 122).
SHH is an upstream regulator of Tbx1 (123, 124) and is required for Gcm2 expression
(121). However, Tbx1 is expressed in 3rd pp endoderm in Gcm2 deficient mice, suggesting
that Shh is upstream of Tbx1 and that Gcm2 is downstream of Tbx1 during PT
organogenesis. Taken together, these data suggest that Tbx1 is necessary of PT
development and may antagonize thymus organogenesis.
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Therefore, the first aim of this thesis addresses the hypothesis that Tbx1 negatively
regulates thymus fate and must be suppressed during thymus organogenesis. As
discussed in Chapter 3, we found that when ectopically expressed in the thymus-fated
domain of the 3rd pp, TBX1 suppresses FOXN1, inhibits TEC proliferation and arrests TEC
differentiation at a very early progenitor stage. However, it does not reverse thymus cell
fate. Our results refute the previously held notion that Tbx1 is required for proper
development of the thymus and clearly demonstrate that Tbx1 is antagonistic to thymus
organogenesis.
Given the notion that SHH and BMP act in opposition to pattern the PT and thymus
in the 3rd pp, respectively, we can now add an additional factor, Tbx1, to the molecular
signaling networks necessary for thymus development. Based on the literature and our
published results, we have developed a model in which Bmp4-mediated expression of
Foxn1, in addition to the downregulation of Tbx1 in the ventral domain of the 3rd pp, is
required for thymus organogenesis (Fig.4). Although these data strongly support our
hypothesis, the molecular mechanisms necessary to downregulate Tbx1 in the ventral
domain of the 3rd pp to allow for the establishment of thymus cell fate, have yet to be
defined.
Therefore, the second aim of this thesis is to identify the genetic pathways necessary
to downregulate Tbx1 expression in the 3rd pp to allow for the establishment, proliferation
and differentiation of TEC progenitors.

31

Figure 4. Model of molecular pathways that establish thymus cell fate in the 3rd pp
endoderm.
Model system of molecular signaling networks necessary for 3rd pp patterning and
thymus cell fate. Bold lines indicate those pathways that are discussed and tested in this
dissertation.
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Figure 4. Model of molecular pathways that establish thymus cell fate in the 3rd pp
endoderm.
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Molecular Mechanisms that Regulate Tbx1 in the 3rd pp Endoderm
The miR-17-92 cluster
MicroRNAs (miRNAs) are a class of highly conserved, small, non-coding RNAs
(ncRNA) that function to post-transcriptionally regulate gene expression (125). The first
miRNA was discovered during a genetic screen studying larval development in C. elegans,
and thousands more have since been identified in vertebrates (126, 127). Genes that
encode miRNAs begin as primary transcripts in a stem-hairpin loop conformation (primiRNA). The RNAse III enzymes, Drosha and Dicer process the pri-miRNA transcript in the
nucleus and cytoplasm, respectively to generate mature miRNA duplexes that are 18-24
nucleotides in length. Either the 5’ or 3’ end of the miRNA duplex is incorporated into the
RNA-induced silencing complex (RISC), binds the 3’ untranslated region (UTR) of its target
and post-transcriptionally silences gene expression (reviewed in (128)). A single miRNA is
capable of silencing numerous genes through imperfect base pairing, thus allowing them to
regulate several developmental and physiological processes.
The miR-17-92 cluster is comprised of six members: miR-17, miR-18a, miR-19a,
miR-20a, miR-19b-1 and miR-92a-1, and is found within an 800 base pair region on
chromosome 13 (129). There is strong evidence implicating miR-17-92 as an important
regulator in hematopoietic and solid tumorigenesis as well as in immune, cardiovascular and
neurodegenerative diseases. Although additional studies have uncovered roles for the
cluster during normal developmental and aging processes, how this miRNA functions
throughout multiple developmental pathways in various organ systems is under
investigation.
The mir-17-92 cluster is highly expressed throughout the embryo and has a
significant impact on the normal development of several organs. Specifically, it contributes
to the proliferation and branching of the lung epithelium, is required for B cell maturation and
is required for cardiomyocyte differentiation (reviewed in (130)). Interestingly, miR-17-92 is
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the first miRNA cluster to be implicated in a human developmental syndrome. Loss of
functional miR-17-92 results in Feingold syndrome; a condition in which patients have
numerous skeletal abnormalities, microcephaly as well as varying degrees of learning
disabilities (131). Mice lacking miR-17-92 recapitulate the phenotypes of Feingold
syndrome, thus making it a good model system to understand its role in the disease as well
to define the role of miR-17-92 in development of other organ systems.

The miR-17-92 cluster and Tbx1
A recent report demonstrated that Tbx1 is expressed in cardiac progenitor cells and
must be downregulated to allow for the differentiation of cardiomyocytes (82). Interestingly,
they found that miR-17-92 directly binds the 3’ UTR of Tbx1 to silence its expression (132).
Furthermore, they reported that Bmp2 and Bmp4 expression are required to initiate the miR17-92-mediated silencing of Tbx1 to promote cardiomyocyte differentiation. Given the role
of Bmp4 in thymus organogenesis coupled with our results showing that ectopic expression
of Tbx1 arrests TEC differentiation, we hypothesize that a similar Bmp2/4-miR-17-92mediated mechanism regulates Tbx1 expression in the 3rd pp endoderm.
Additional data has shown that TBX1 binds SMAD1 and suppresses Bmp4 signaling,
suggesting a regulatory loop (133). Based on these data and our results showing that Tbx1
is indeed regulated by miR-17-92 in the 3rd pp endoderm, we have developed a model in
which Tbx1 is regulated by a Bmp-miRNA-mediated pathway to specify thymus fate in the
3rd pp (Fig.4). Chapter 5 of this thesis will focus on the role of miR-17-92 regulation of Tbx1
in the 3rd pp endoderm and the subsequent development of the fetal thymus.
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CHAPTER2: Materials and Methods
Mice
We generated a conditional Tbx1 knock-in strain by targeting a Tbx1 inducible
expression cassette to the endogenous Rosa26 locus to generate a R26iTbx1 allele. In this
Tbx1 inducible cassette, a full-length mouse Tbx1 cDNA and an IRES-GFP were inserted
downstream of a floxed stop cassette (vector provided by Dr. A. McMahon). Expression of
the R26iTbx1 allele was activated in TECs by crossing R26iTbx1 females with Foxn1Cre males
(134). R26iTbx1/+ and R26+/+ littermate controls were maintained on a mixed C57Bl/6 genetic
background at the MD Anderson Cancer Center Science Park in accordance with the
guidelines set forth by the Association for the Accreditation of Laboratory Animal Care.
Timed pregnancies were set up in the evening and monitored daily thereafter. The day of
vaginal plug was considered embryonic day 0.5. Morphological cues and somite staging
were used to determine embryonic stage. Yolk sac DNA was genotyped using:
Rosa26 forward 5’TTGCAATACCTTTCTGGGAGTT-3’,
Rosa26 reverse 5’-AACCCCAGATGACTCCTATCCT-3’ and
β-galactosidase reverse 5’-GACAGTATCGGCCTCAGGAAG-3’.
All experiments were performed in accordance with the MD Anderson Animal Care and Use
Committee.
The miR-17-, miR-17-92OE , Pax3Sp and Tbx1Fgf8 mouse models have been
previously described and were obtained from the Jackson Laboratory (Bar Harbor, ME).
The Foxn1Cre mice were gifted from the Manley Lab at the university of Georgia (Athens,
GA).
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Histochemistry and Immunohistochemistry
Embryos intended for either OCT or paraffin embedding were dissected into cold
PBS and age-matched by somite counting. Those harvested for frozen sections were fixed
in filtered 4% paraformaldehyde (PFA) dissolved in phosphate buffered saline solution
(PBS) for 15 min (E11.5), 30 min (E13.5) or 40 minutes (E15.5). After fixation, the embryos
were washed three times, for five minutes in PBS and placed in 20% sucrose (dissolved in
PBS) overnight at 4°C. The next day, embryos were removed from the sucrose, embedded
in OCT and stored at -80°C until ready for sectioning. Sagittal or transverse serial sections
of the embryonic tissue were cut at 7µm on a Thermo Shandon Cryostat (Cryotome SME,
SN:CS3094B0110) onto Superfrost Plus microscope slides (Fisher Scientific, Catalog
Number: 12-550-15). When ready for analysis, slides were placed on the bench top and
allowed to warn to room temperature for 5 minutes. They were then washed for 5 minutes
in slide mailers containing PBST (PBS with 0.05%Triton X-100, BioRad, Catalog Number:
161-0407) at room temperature. The primary antibody mixture was prepared as follows:
primary antibody at the appropriate dilution, 5% donkey serum and 0.05% Triton X-100 in
PBS. 120µl of the primary antibody mix was added to each slide, coverslipped with parafilm
and incubated overnight at 4°C in a humidified chamber. The next day, slides were rinsed
three times, at 5 minutes per wash in PBST. The secondary antibody solution contained:
host-specific secondary antibody diluted at 1:400 in 0.05% Triton X-100 in PBS. 120µl of the
secondary antibody solution was applied to each slide, coverslipped and incubated in the
dark for 1 hour at room temperature. Slides were washed in PBST two times, for five
minutes, then incubated with 4’,6-diamidino-2-phenylindole (DAPI) for 3 min at room
temperature. After DAPI staining, three, five minute PBS washes in slide mailers were
performed in preparation for mounting. Finally, slides were mounted with ProLong® Gold
antifade reagent (Life Technologies) and coverslipped for imaging.
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Embryos collected for paraffin embedding were fixed for a period of 1 hour to
overnight (depending on the tissue size) in 4% PFA (prepared as described above). After
PFA fixation, embryos were washed for five minutes in PBS, then dehydrated in an ethanol
gradient as follows: 30%, 50%, 70%, 80%, 90%, 95%, then 100%. Each wash step was
done at 4°C for 30 minutes, with the last 100% EtOH wash going overnight at 4°C. Embryos
were permeabilized with xylenes and embedded in paraffin in accordance with general
embedding protocols. Serial sections were cut at 7µm on a Leica ThermoShandon Finesse
325 microtome and allowed to dry on a plate warmer overnight at 37°C, then stored at 4°C
until ready for analysis. Slides were allowed to warm to room temperature, placed in slide
mailers, dewaxed in xylene and rehydrated through a methanol gradient as follows: two, five
minute xylene washes, one minute in each wash step: 100% MeOH, 100% MeOH, 95%
MeOH, 70% MeOH and cold tap water. Then slides were subjected to an antigen retrieval
to reverse PFA crosslinks. Slides were transferred from tap water directly into slides mailers
containing AR buffer (10mM Na3C6H5O72H2O, pH 6, 0.05% Tween 20) in a boiling (95°C 100°C) water bath for 30 minutes. The amount of time in the AR buffer can be adjusted to
lengths between 20 and 60 minutes. Remove slide mailers from the boiling water bath and
allow slides to slowly cool to room temperature in the AR buffer (approximately 15 minutes).
Prior to adding the primary antibody mixture, wash slides in 0.05% PBST for 1 minute.
Prepare primary antibody mixture as follows: primary antibody at the appropriate dilution
and 10% donkey serum into 0.05% Triton X-100 in PBS. Add 120µl of the primary antibody
mix to each slide, coverslip with parafilm and incubate overnight at 4°C in a humidified
chamber. The next day, slides were washed three times, five minutes each on a rocker.
Dilute secondary antibody in PBST and add 120µl per slide, coverslip and incubate at room
temperature for 30 minutes to 1 hour in the dark. Repeat wash steps in the dark, and then
add DAPI for three minutes as described above. Finally, slides were rinsed in PBS for two,
five-minute washes and mounted using ProLong Gold.
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Paraffin embedded tissues collected for hematoxalyn and eosin (H&E) staining were
processed according to standard techniques. Primary antibodies used were goat anti-Foxn1
(1:200, Santa Cruz, G-20), rabbit anti-Tbx1 (1:100, Abcam), rabbit anti-Gcm2 (1:200,
Abcam), rabbit anti-Foxg1 (1:50, Abcam), rat anti-BrdU (1:10, Serotec), goat anti-β5t (1:200,
MBL), rat anti-Ly75 (1:100, Abcam), K14 (1:400, Covance), Biotinylated UEA1 (1:200,
Vector), rabbit anti-Aire-1 (1:50 Santa Cruz, M-300), rabbit anti-Claudins 3 and 4 (1:200,
Invitrogen), K5 (1:400, Covance), Plet-1 (kindly provided by Dr. Claire Blackburn), Ikaros
(1:100, Santa Cruz, M-20). All secondary antibodies were conjugated with DyLight 488
(Jackson Immunoresearch).
BrdU (300µl of 10mg/ml) was injected by the intraperitoneal (IP) route into pregnant
females and embryos were harvested after a 90 minute chase. Cells from serial sections
were counted based on expression of FOXN1, GCM2, TBX1, and/or BrdU using Cell Profiler
(Broad Institute) or Imaris (BITPLANE). Images were taken on a Leica DM600b using LAS
X Software.

Flow Cytometry
Embryonic TEC analysis was adapted from the Gray et al. protocol (135). For TEC
analysis, fetal thymi were dissected out of the embryo into cold RPMI (ThermoScientific)
containing 5% fetal calf serum and processed as described. Then, the thymi were
incubated in 0.125% Collagenase (Sigma) and 0.1% DNase (Roche) for three 10 minute
periods in a 37°C water bath until the tissue was completely digested. Specifically, after
each incubation period, the tissue was gently aspirated using a 1 mL pipette and
supernatant was collected in a separate 50 mL conical containing FACS wash buffer (PBS
pH 7.2, 0.005M EDTA, 2% fetal calf serum). The single cell suspensions were spun down
at 1250 rpm for 4 minutes to generate a cell pellet. The supernatant was discarded and
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cells were re-suspended in 200µl -2000µl, depending on the size of the cell pellet and total
cellularity was calculated using a Countess (Invitrogen).
For analysis of thymocyte subsets, fetal thymi were pressed through a 70µm strainer
(Fisher). Single cell suspensions were centrifuged at 1500 rpm for 5 minutes as cellularity
was calculated as described above. Cells were resuspended in FACS wash buffer and
aliquoted into single color control and data tubes, and then stained with fluorochromeconjugated antibodies in FACS buffer for 20 minutes on ice. After incubation with
antibodies, cells were washed in 1 mL of FACS wash buffer, vortexed, spun down as
described above and re-suspended in PBS for analysis. Propidium iodide (Invitrogen) was
added (0.5 µg/ml) to each sample prior to analysis to exclude dead cells. Anti-CD326 (clone
G8.8) conjugated to PE/Cy7, anti-I-A/I-E (clone M5/114.15.2) and anti-CD25 (clone PC61)
conjugated to Pacific Blue, anti-CD326 (Clone G8.8) conjugated to allophycocyanin and
anti-CD117 (clone 2 B8) conjugated to allophycocyanin -Cy7 were purchased from
Biolegend. Anti-CD44 (clone IM7) conjugated to allophycocyanin, anti-CD8α (clone 53-6.7)
conjugated to PE-Cy7, anti-CD45 (clone 30-F11) conjugated to PerCp-Cy5.5 were
purchased from eBioscience. Anti-CD4 (clone RM4-5) conjugated to Qdot® 605 was
purchased from Invitrogen. To exclude erythrocytes, granulocytes, dendritic cells,
macrophages and NK cells from the thymocyte analyses, the following antibodies, all
conjugated to PE-Cy5 were purchased form eBioscience: TER-119, CD11c (cloneN418),
CD11b (clone M1/70), NK-1.1 (clone PK136) and Ly-6G (clone RB6-8C5). Cells were
analyzed or sorted on a FACS Aria II (BD Science). Data were analyzed using FlowJo
software (Tree Star).

RNA Isolation, cDNA Synthesis and Real-time Quantitative Reverse Transcriptase
Polymerase Chain Reaction (qRT-PCR)
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FACS sorted R26iTbx1 and control TECs from a given litter were pooled and lysed in
Trizol (Ambion) and stored at -80°C until ready for RNA isolation. RNA was isolated using a
protocol adopted from the Ehrlich lab (The University of Texas, Austin, TX). The cells in
Trizol were removed from -80°C and 2µl of linear acrylamide (Ambion) was added to each
tube, followed by 200µl of cholorform. Each sample was shaken vigorously for 15 seconds
and incubated on ice for 10 minutes. Then the cell samples were centrifuged at 13,000 rpm
for 15 minutes at 4°C. During the 15-minute spin, 2µl of linear acrylamide was added to
new, labeled tubes and the upper, translucent layer of the chloroform mixture was added to
the new tube containing the linear acrylamide. As much of the upper, translucent layer was
transferred as possible, while avoiding contamination from the middle layer. Then, 500µl of
isopropanol was added to each tube, shaken vigorously for 15 seconds, then stored at
-20°C overnight.
The following day, the samples were removed from the freezer and centrifuged at
13,000 rpm for 15 minutes at 4°C. The supernatant was removed using a pipette, without
disturbing the pellet. Then, 1mL of 70% ethanol/DEPC water was added to each tube. The
tubes were gently inverted and centrifuged at 7,500 rpm for 10 minutes at 4°C. The alcohol
was removed using a pipette, and the pellet was allowed to air dry. Finally, the cell pellet
was re-suspended in 5µl of RNase-free DEPC water and stored at -80°C for cDNA
synthesis.
First-strand cDNA was synthesized using a SuperScript® III First-Strand cDNA
synthesis kit (Invitrogen) according to the manufactuer’s protocol. TaqMan® Gene
Expression Master Mix (Applied Biosystems) and TaqMan primers (Applied Biosystems)
were used for quantitative reverse transcriptase PCR (qRT-PCR) analysis of Foxn1, Tbx1
and α-tubulin (endogenous control). Samples were analyzed using a LightCycler® 480
(Roche). In each experiment, comparators were set to a value of 1. All experiments were
repeated 3 times and analyzed using the ΔΔCt method.
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Primer Sequences:
Foxn1: Mm00433946_m1
Tbx1: Mm00448848_m1
α-tubulin: Mm00846967_g1

In Situ Hybridization
The dissection station and all dissection tools were wiped down with RNase Off
(Ambion) prior to harvesting embryos. Embryos were dissected into cold DEPC
(diethylpyrocarbonate)-treated PBS and fixed in 4% PFA (DPEC PBS) overnight. The next
day, tissue was washed in PBS, dehydrated in an ethanol gradient, permeabilized using
xylenes and embedded in paraffin, as previously described. However, all of these steps
were performed in RNase-free conditions. Serial sections were cut at 14µm on a Leica
ThermoShandon Finesse 325 microtome that had been treated with RNase off and then
slides were allowed to dry on a plate warmer overnight at 37°C, then stored at 4°C until
ready for analysis.
Prior to beginning the in situ, slide mailers were soaked in 1M NaOH overnight,
rinsed with DEPC water and autoclaved. Slides were allowed to warm to room temperature
on a bench top that had been thoroughly wiped down with RNase wipes. Tissue sections
were then dewaxed in two, 10 minute xylene washes followed by rehydration steps in an
ethanol/DEPC PBS gradient: 100%, 100%, 90%, 70%, 30%. Slides were incubated in each
ethanol wash for two minutes at room temperature then washed in DEPC PBS for 5
minutes. 200µl of hybridization solution containing 0.5µg/mL of dig-labeled riboprobe was
applied to each slide and then coverslipped using parafilm. Slides were incubated overnight
in a humidified chamber with 2X SSC (DEPC) and formamide (in the bottom of the chamber)
at 65°C.
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The following day, slides were removed from the humidified chamber, transferred
into slide mailers containing prewarmed 0.5X SSC, 20% formamide and washed at 65°C for
20 minutes. This step was repeated for a total of three washes. While slides were
incubating at 65°C, 1X NTE solution was warmed to 37°C and after the third
SSC/formamide wash, slides were then rinsed in 1X NTE for 15 minutes. Slides were
washed for 30 minutes in pre-warmed NTE containing 10µg/mL RNase A (Sigma) at 37°C to
minimize background, then washed in NTE alone for 15 minutes at 37°C. After the NTE
washes were complete, slides were once again washed in pre-warmed 0.5X SSC, 20%
formamide for a total of four 20 minute washes at 65°C. Washes can be extended to one
hour each, if necessary. Subsequently, slides were washed for 30 minutes in 2X SSC at
room temperature. During this time, a 1% blocking solution was prepared by dissolving
blocking powder in MAB at 55°C. Slides were incubated in slide mailers containing the 1%
blocking solution in MABT for one hour at room temperature. During this hour, anti-Dig-AP
antibody diluted to a concentration of 1:100 in 1% blocking solution/MABT was incubated on
ice. Finally, the slides were placed in a humidified chamber containing MAB and 200µl of
the antibody solution was added to each slide and coverslipped using parafilm. The
humidified chamber containing slides was incubated at 4°C overnight.
At the beginning of day 3, the parafilm coverslips were removed and the slides were
placed in mailers and washed in TBST at room temperature for the following amounts of
time: 10 minutes, 20 minutes then six, 1 hour washes. After the last TBST wash, slides
were washed for 10 minutes in AP buffer at room temperature. During the 10 minute AP
wash, enough BM Purple to add 200µl to each slide was allowed to warm to room
temperature in the dark. In a humidified chamber containing distilled water, 200µl of BM
Purple was added to each slide and coverslipped with parafilm. The humidified chamber
was placed at room temperature in the dark and monitored daily until the color reaction was
complete. Each day, the slides were washed in AP buffer for 10 minutes and new BM
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purple solution was added. Once the color reaction was complete, the staining process was
stopped by rinsing slides in PBS. Tissue sections were fixed in 4% PFA for 20 minutes then
washed for 1 minute in PBS containing 5µM EDTA at 4°C. Slides were counterstained with
nuclear fast red, then dehydrated along a methanol/PBS gradient: 30%, 50%, 70%, 90%,
100%, 100%. Each methanol wash was performed at room temperature for 5 minutes.
Finally slides were placed in xylene for 5 minutes and mounted with cytoseal and a glass
coverslip for imaging. Images were captured using an Aperio (Scan Scope) and an Olympus
bright field microscope.
The following probes were used for ISH analysis: miR-17, miR-19a and miR-92a
(Exiqon) and Fgf8 and Bmp4 (kindly provided by Dr. Virginia Bain).
ISH Solutions:
1. 20X SSC- 175g NaCl, 88g Na3C6H5O72H2O (sodium citrate dehydrate), add
DEPC water to 1L
2. 10X NTE- 292g NaCl, 100mL 1M Tris (pH 7.5), 100mL 0.5M EDTA, add DEPC
water to 1L and autoclave
3. AP Buffer- 1mL 5m NaCl, 2.5mL 1M MgCl2, 50µl Tween-20, 2.5mL 2M Tris (pH
9.75), 2mM Levamisole, add water to 50mL
4. MAB- 5.8g Maleic acid, 4.4g NaCl, pH to 7.5 using NaOH, add water to 500mL,
autoclave
5. MABT- Add 0.1% Tween-20 to MAB
6. 10X TBST (make fresh solution each time)- 8g NaCl, 0.2g KCl, 25mL 1M Tris
(pH 9.75), add water to 99 mL then add 1mL of Tween-20
7. Rnase A (10mg/mL) – Dissolve 0.01g of Rnase A in 900µl of 0.01M sodium
acetate (pH 5.2) at 100°C for 15 minutes. Allow to cool to room temperature, add
100µl of 1M Tris
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8. Hybridization Buffer- 25mL formamide, 12.5 mL 20X SSC (DEPC), 5.0mL 50%
dextran sulfate, 6.5mL DEPC water, 50µl Heparin (50µg/µl), 50 µl Tween-20,
400µl 1M Na3C6H5O72H2O, 0.005g tRNA powder/ Filter sterilize, aliquot and
store at -80°C

Statistics
Prism 6.0 (GraphPad version 6.0b; Sand Diego, CA) and Microsoft Excel were used for
statistical analyses. We used a Student’s t test to evaluate differences between controls and
mutants regarding the number of cells expressing FOXN1, GCM2, TBX1 and/or BrdU. A
p-value <0.05 was considered statistically significant.
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Chapter 3: Ectopic TBX1 suppresses thymic epithelial cell differentiation and
proliferation during thymus organogenesis
Note this chapter is based on: Reeh, K. A., K. T. Cardenas, V. E. Bain, Z. Liu, M.
Laurent, N. R. Manley, and E. R. Richie. 2014. Ectopic TBX1 suppresses thymic epithelial
cell differentiation and proliferation during thymus organogenesis. Development 141: 29502958. With permission from the copyright holder.

INTRODUCTION
By E11.5, the thymus- and parathyroid-fated domains can be recognized by Foxn1
and Gcm2 expression, respectively. However, although these transcription factors regulate
differentiation, they do not specify thymus versus parathyroid fate (57, 87, 121). A Hox-PaxEya-Six cascade is implicated upstream of thymus specification, but has not been directly
linked to the establishment of thymus fate (106). Additional transcription factors with
restricted expression patterns in the 3rd pp have been identified, but their role in thymus fate
is not yet established (108). Thus, the transcription factors and molecular pathways that
specify thymus fate and regulate thymus organogenesis are not yet defined.
Earlier reports suggested that the T-box transcription factor TBX1 is essential for
thymus organogenesis because thymus aplasia is a characteristic feature of Tbx1
homozygous deletion mutants (40, 114, 121, 136). However, TBX1 is required for
segmentation of the pharyngeal apparatus and in its absence, the pharyngeal pouches do
not develop (112, 114, 115, 118, 119). Therefore, the athymia observed in the absence of
Tbx1 is a secondary consequence of defective pouch formation. As a result, the potential
role of Tbx1 in thymus organogenesis cannot be determined from analysis of Tbx1 null
embryos. In the pharyngeal region, Tbx1 is expressed in arch mesenchyme and in pouch
endoderm, but not by NCCs (112). Thymus hypoplasia was reported in a transgenic line
expressing a Tbx1 transgene in the Tbx1 expression domain (117). Since the Tbx1
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transgene was widely expressed in mesenchyme and endoderm, the mechanism(s) leading
to thymus hypoplasia are unclear. By E10.5 Tbx1 expression in the 3rd pp is restricted to the
parathyroid domain and excluded from the thymus domain (112, 122, 137), suggesting that
Tbx1 may be necessary for parathyroid formation, but antagonistic to thymus development.
This notion is supported by reports showing that Tbx1 is a downstream target of SHH
signaling (123, 124) and that Foxn1 expression is expanded in the 3rd pp of Shh null mice
(86).
To test the hypothesis that Tbx1 expression in 3rd pp endoderm suppresses thymus
fate and/or TEC differentiation, we generated a novel mouse strain in which a stop-floxed
Tbx1 allele was knocked into the ubiquitously expressed Rosa26 locus. We used Foxn1Cre
to activate Tbx1 expression in the thymus fated domain of the 3rd pp. Here we show that
ectopic Tbx1 expression in the ventral 3rd pp suppresses Foxn1 expression, alters patterning
of organ specific domains, inhibits TEC proliferation and blocks TEC differentiation at an
early progenitor stage, but does not reverse thymus fate. The results support the hypothesis
that Tbx1 negatively regulates TEC growth and differentiation and that extinction of Tbx1
expression in 3rd pp endoderm is a prerequisite for thymus organogenesis.

RESULTS
Foxn1Cre activates ectopic expression of the R26iTbx1 allele in the ventral domain of the
3rd pp
Tbx1 is expressed throughout 3rd pp endoderm at E9.5, but by E10.5 is restricted to
the dorsal, parathyroid fated domain (112, 121, 122, 138). Foxn1 expressing cells are
present in the dorsal 3rd pp and extend into pharyngeal endoderm in the absence of SHH, a
positive regulator of Tbx1 expression (86, 123, 124). Taken together, these data suggest
that TBX1 antagonizes thymus development. Therefore, we used a gain-of-function
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approach to test this hypothesis. Tbx1 cDNA and an IRES-GFP tag were inserted into a
modified Rosa26 targeting vector containing a floxed stop cassette to generate a knock-in
strain hereafter referred to as R26iTbx1 (Fig. 5). This allele activates expression of both Tbx1
and EGFP after Cre-mediated deletion of the stop cassette.
We used Foxn1Cre to activate ectopic Tbx1 expression in the ventral, thymus fated
domain of the 3rd pp beginning at ~E11.25 (134). Thymus fate is specified in 3rd pp
endoderm as early as E9.5-E10.5 prior to expression of Foxn1, which is essential for TEC
differentiation and proliferation (reviewed in (51, 106)). Therefore, Foxn1Cre activates
expression of the R26iTbx1 allele in ventral 3rd pp endoderm after the cells commit to a
thymus fate and are beginning to differentiate. Immunohistochemical (IHC) analysis of GFP
expression in the Foxn1Cre/+;R26iTbx1/+ 3rd pp verified the predicted ectopic expression of
R26iTbx1 in the ventral, but not in the dorsal domain and confirmed the absence of a GFP
signal in Foxn1Cre/+;R26+/+ controls (Fig. 6). Continued expression of the R26iTbx1 allele in
fetal thymi throughout ontogeny was confirmed by FACS analysis of GFP expression, which
also verified restriction of the GFP signal to EpCAM+ CD45- TECs (Fig. 6).

Ectopic TBX1 expression suppresses FOXN1 but does not alter GCM2 expression
We asked whether ectopic expression of Tbx1 in the ventral domain altered
patterning of the 3rd pp at E11.5. IHC staining of serial sections from Foxn1Cre;R26+/+
controls confirmed that endogenous TBX1 is restricted to the dorsal, parathyroid fated
domain (Fig. 7A), whereas FOXN1 is restricted to the ventral, thymus fated domain (Fig. 7A,
7C). FOXN1 and TBX1 co-expressing cells were not found in the control 3rd pp. In contrast
to the restricted expression of TBX1 in the control 3rd pp at this stage, we found an
increased number of TBX1 positive cells located in both the ventral and dorsal regions of the
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Figure 5. Generation of Rosa26Tbx1 conditional knock-in mice.
(A) Schematic illustration of the Rosa26 genomic wild-type (WT) locus, targeting
vector and targeted knock-in (KI) locus. Black triangles represent the loxP sites. The black
bar represents the 5’ probe used for the Southern Blot screen. Arrows represent the primers
used for the PCR screen for the targeting event, which amplify a 1.2 kb PCR product from
the KI allele, but not the wild-type allele. (B) Southern blot analysis of genomic DNA from
Neo resistant ES cell lines after electroporation. The genomic DNA samples were digested
with Hind III and hybridized with the 5’ probe shown in S1A. The 5’ probe hybridizes with a
4.3 kb band from the Rosa26 WT allele and a 3.6 kb band from the R26iTbx1 allele. (C) PCR
genotyping analysis of genomic DNA from R26iTbx1 strain in which a 298bp band represents
the WT allele and a 456bp band represents the mutant allele.
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Figure 5. Generation of Rosa26Tbx1 conditional knock-in mice.
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Figure 6. Ectopic Tbx1 is expressed in the thymus-fated domain of the 3rd pp and in
TECs, as reflected by GFP expression.
(A,B) Representative IHC stains of sagittal sections from E11.5 3rd pp show GFP
expression in the R26iTbx1 mutant (B) but not the control (A) and verifying ectopic expression
of Tbx1 in the ventral, but not dorsal, domain of the pouch. (C) FACS analysis of E15.5
control and Foxn1Cre;R26iTbx1/+ thymi showing electronic gates set around EpCAM+ CD45TECs (red), CD45+ thymocytes (blue) and EpCAM-CD45- non-TEC stromal cells (green). (D)
Histograms showing GFP expression in the corresponding TEC, thymocyte and non-TEC
stromal cell subsets. The GFP signal in Foxn1Cre;R26iTbx1/+ TECs confirms continued
expression of the R26iTbx1 allele in mutant TECs. The data also confirm that the GFP signal
is restricted to EpCAM+ CD45- TEC subset in the mutant thymus and is not detected in
control TECs.
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Figure 6. Ectopic Tbx1 is expressed in the thymus-fated domain of the 3rd pp and
in TECs, as reflected by GFP expression.
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Figure 7. Ectopic TBX1 in the ventral 3rd pp reduces the number of FOXN1 positive
cells.
(A-D) Representative IHC stains of sagittal sections from 3rd pp of
Foxn1Cre;R26+/+ control and Foxn1Cre;R26iTbx1/+ E11.5 embryos. (A, B) TBX1 (red) is
restricted to the dorsal parathyroid-fated domain of the control, but is present throughout
the mutant 3rd pp. Note the marked reduction in FOXN1 positive cells (green) in the
mutant 3rd pp. A few cells in the mutant 3rd pp are FOXN1 positive and co-stain for TBX1
(yellow). (C) GCM2 (red) is present in parathyroid-fated cells in the dorsal domain of the
control 3rd pp. (D) Ectopic TBX1 does not affect localization or frequency of GCM2
positive cells in the mutant 3rd pp. Scale bars: 50 µm (E) Bar graph of the percentage ±
SD of 3rd pp cells that are positive for FOXN1, TBX1 or GCM2 (n = 4 control and 4
Foxn1Cre;R26iTbx1/+ 3rd pps). **P<0.02.
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Figure 7. Ectopic TBX1 in the ventral 3rd pp reduces the number of FOXN1 positive
cells.
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Foxn1Cre;R26iTbx/+ 3rd pp (Fig. 7B, E). The presence of ectopic TBX1 protein in the ventral
3rd pp is consistent with the GFP staining pattern observed in the Foxn1Cre;R26iTbx/+ 3rd pp
(Fig. 5). Ectopic TBX1 in the ventral domain resulted in a profound and rapid reduction
in the frequency of 3rd pp cells containing detectable levels of FOXN1 (Fig. 7B, D, E).
Gcm2 was previously proposed to be a downstream target of Tbx1 (121,
139r1223). However, ectopic Tbx1 expression had no discernable effect on the number
or localization of GCM2 positive cells (Fig. 7D, E). GCM2 was localized to the dorsal,
anterior region of the control 3rd pp, and this restricted expression pattern was
maintained in the Foxn1Cre;R26iTbx/+ 3rd pp. Therefore, these data demonstrate that
ectopic expression of Tbx1 is not sufficient to induce Gcm2 expression in the ventral
domain of the 3rd pp, suggesting that additional regulators are involved in controlling
Gcm2 expression.

Ectopic TBX1 expression in the E11.5 3rd pp does not reverse thymus fate
Owing to the severe reduction in FOXN1 positive cells and failure to expand
GCM2, the majority of cells in the ventral domain of the Foxn1Cre;R26iTbx/+ 3rd pp express
neither FOXN1 nor GCM2 (Fig. 7B, D, E). To determine if these cells are no longer
committed to a thymus fate, we examined expression of additional factors that are
expressed by thymus specified cells. We previously reported that at E11.5, thymus-, but
not parathyroid-fated cells in the 3rd pp express IL7, a cytokine that is essential for
thymocyte differentiation and survival (12, 140). Moreover, IL-7 is expressed by
immature TECs in the thymic rudiment of FOXN1 deficient nude (Foxn1nu/nu) mice (12).
Therefore, IL7 is a Foxn1 independent marker of thymus fated cells. Quantitative RTPCR analysis demonstrated comparable levels of IL-7 mRNA in 3rd pp cells of
Foxn1Cre;R26iTbx/+ and control embryos (Fig. 8A).
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Figure 8. Ectopic TBX1 does not affect expression of IL-7 or FOXG1 in the ventral
3rd pp.
(A) Real-time quantitative PCR analysis shows equivalent IL7 mRNA levels in 3rd
pp dissected from E11.5 control or Foxn1Cre;R26iTbx1/+ embryos. (n = 6 control and 6
Foxn1Cre;R26iTbx1/+) (B) Representative IHC stain showing a sagittal section of E11.5 3rd
pp. FOXG1 (red) and FOXN1 (green) are co-expressed in the ventral domain; DAPI
(blue). (C) Representative IHC stain of a sagittal section of mutant 3rd pp showing
abundant FOXG1 in the ventral domain despite the severe reduction in FOXN1. (D, E)
Single color images of FOXN1 staining. Scale bars: 50 µm.
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Figure 8. Ectopic TBX1 does not affect expression of IL-7 or FOXG1 in the ventral
3rd pp.
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FOXG1 is a transcription factor that is initially expressed in the ventral domain of
the 3rd pp by E10.5, preceding Foxn1 (108). Similar to IL7, Foxg1 is expressed in the
Foxn1nu/nu thymic rudiment (Wei and Condie, unpublished data). IHC analysis of serial
sections in the control 3rd pp showed that FOXG1 overlaps with FOXN1 in the ventral
domain and is excluded from the dorsal, GCM2 domain (Fig. 8B, D). Interestingly,
FOXG1 is abundantly expressed by the FOXN1 negative cells in the Foxn1Cre;R26iTbx/+
ventral 3rd pp domain (Fig. 8C). The robust expression of IL-7 and FOXG1 in the
Foxn1Cre;R26iTbx/+ ventral 3rd pp demonstrates that ectopic expression of Tbx1 does not
repress or reverse thymus fate, but instead is selectively acting through repression of
Foxn1.

Ectopic TBX1 expression reduces proliferation of GCM2-negative cells in the ventral
3rd pp
Despite the severely reduced levels of Foxn1 expression in the 3rd pp of
Foxn1Cre;R26iTbx/+ embryos, thymic primordia formed, detached from the pharynx and
migrated to a normal position above the heart in a timely manner (Fig. 9) (51). These data
are consistent with the conclusion that cells in the ventral 3rd pp remain specified to a
thymus fate after ectopic Tbx1 expression. However, Foxn1Cre;R26iTbx/+ fetal thymi are
severely hypoplastic throughout ontogeny and remain so in the postnatal period (Fig. 9 and
data not shown). The hypoplastic phenotype is not surprising given that FOXN1 is essential
for TEC proliferation (57, 99, 141, 142).
To determine the cellular mechanism(s) by which ectopic TBX1 expression results in
thymus hypoplasia, we analyzed the frequency of proliferating and apoptotic cells in the
ventral domain of the 3rd pp. Due to the paucity of FOXN1 positive cells caused by ectopic
TBX1, we determined the percentage of BrdU incorporating cells in GCM2 positive
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Figure 9. Thymic lobes are hypoplastic throughout ontogeny in Foxn1Cre;R26iTbx1/+
embryos.
(A-F) H&E stained transverse sections show that Foxn1Cre;R26iTbx1/+ thymic lobes
are smaller than controls at each developmental stage. Asterisks indicate thymic lobes. (A,
B) E12.5 (C, D) E14.5; (E, F) E17.5. Scale bars: 50 µm.
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Figure 9. Thymic lobes are hypoplastic throughout ontogeny in Foxn1Cre;R26iTbx1/+
embryos.
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compared to GCM2 negative 3rd pp domains. Ectopic Tbx1 expression decreased the
frequency of proliferating cells in the GCM2-negative domain (Fig. 10A-C). In contrast, we
found no difference in the frequency of proliferating GCM2-positive cells. To determine if
ectopic Tbx1 expression enhanced apoptosis in the 3rd pp, we stained sections for cleaved
caspase 3. No difference was observed in the frequency of apoptotic 3rd pp cells in
Foxn1Cre;R26iTbx/+ compared to control embryos (data not shown). These data demonstrate
that TEC proliferation, but not survival, is compromised by ectopic expression of Tbx1 in the
thymus fated domain.

TEC differentiation is impaired by ectopic TBX1 expression
Given that FOXN1 is required for TEC differentiation (57, 87, 88, 99, 143), we
predicted that this process would be impaired in Foxn1Cre;R26iTbx/+ thymi. To test this
hypothesis, we first assessed expression of MHC Class II (MHCII), an early differentiation
marker that is expressed on wildtype TECs beginning at E12.5 in a Foxn1 dependent
manner (57, 99, 144, 145). Whereas most TECs in E15.5 control thymi expressed high
levels of MHCII, there was a five to ten fold reduction in the frequency of MHCIIhi TECs in
Foxn1Cre;R26iTbx/+ mutants, indicating an early block in TEC differentiation (Fig. 11A). We
isolated TECs by cell sorting into MHCIIhi and MHCIIneg-lo populations for qRT-PCR analysis
using the sort gates shown in Figure 11A. As previously reported (99), MHC IIhi TECs from
controls expressed higher levels of Foxn1 transcripts than MHCIIlo TECs (Fig. 11B). Neither
TEC subset isolated from control thymi expressed significant levels of Tbx1 (Fig. 11C). In
contrast, both MHCIIhi and MHCIIneg-lo TECs from Foxn1Cre;R26iTbx/+ thymi expressed very
low levels of Foxn1 and high levels of Tbx1 mRNA (Fig. 11B, C). These data are consistent
with the notion that TBX1 suppression of Foxn1 causes decreased TEC differentiation.
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Figure 10. Proliferation is reduced in the Foxn1Cre;R26iTbx1/+ thymus-fated 3rd pp
domain.
(A, B) BrdU (10 mg/ml) was injected into pregnant females 1.5 hrs prior to obtaining
E11.5 embryos. IHC staining for BrdU (teal) identifies proliferating cells in the GCM2 positive
(red), parathyroid fated domain and the GCM2 negative thymus fated domain of the 3rd pp
from control (A) and Foxn1Cre;R26iTbx1/+ (B) embryos. Scale bars: 50 µm. (C, D) Bar graphs
showing the frequency of BrdU labeled cells that are GCM2 negative or GCM2 positive.
Data show percentage ± SD for 8 control and 8 Foxn1Cre;R26iTbx1/+ 3rd pps. **P<0.005.

62

Figure 10. Proliferation is reduced in the Foxn1Cre;R26iTbx1/+ thymus fated 3rd pp
domain.

63

Figure 11. Ectopic TBX1 blocks TEC differentiation and suppresses Foxn1
expression.
(A) Flow cytometric analysis of MHC class II expression on EpCAM+ CD45- control
and Foxn1Cre;R26iTbx1/+ TECs. Note that the majority of control TECs are MHCIIhi whereas
most Foxn1Cre;R26iTbx1/+ TECs are MHCIIneg-lo (B,C) Representative bar graphs of qRT-PCR
analysis showing Foxn1 (B) or Tbx1 (C) expression in E15.5 control and Foxn1Cre;R26iTbx1/+
TECs. MHCIIhi and MHCIIneg-lo were obtained by FACS sorting using the indicated gates.
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Figure 11. Ectopic TBX1 blocks TEC differentiation and suppresses Foxn1
expression.
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FOXN1-positive TECs express cTEC and mTEC markers, and segregate from TBX1
positive TECs
By E15.5, a small number of FOXN1 positive TECs were present in the
Foxn1Cre;R26iTbx/+ thymi; these TECs had low TBX1 levels, presumably due to down
regulation of or failure to activate R26iTbx. IHC analysis revealed that this small number of
FOXN1 positive TECs localize predominantly to the central region of each lobe (Fig. 12B),
whereas FOXN1 expressing TECs are distributed throughout control thymi at E15.5 (Fig.
12A). Most TECs in Foxn1Cre;R26iTbx/+thymic lobes continued to express high levels of TBX1
and low to undetectable levels of FOXN1. These cells were concentrated towards the outer
region of each lobe (Fig. 12B). A similar pattern of TBX1 and FOXN1 expression was
observed at E17.5 (Fig. 13).
To determine if TECs in Foxn1Cre;R26iTbx/+ thymi were committed to either cTEC or
mTEC lineages, we analyzed additional lineage specific TEC markers. The
thymoproteosome subunit, b5t as well as the surface receptor, CD205 are expressed in a
FOXN1-dependent manner at early stages of cTEC differentiation (92, 144, 146). As
expected, the majority of cTECs in the control thymus were positive for both CD205 and b5t
(Fig. 12C, E). In contrast, only a subset of TECs in Foxn1Cre;R26iTbx/+ thymi expressed b5t or
CD205. TECs expressing these markers were primarily found in the center of each lobe,
where FOXN1 positive cells were also located (Fig 12D, F).
K14 expression and binding of the lectin, Ulex europeaus agglutinin 1 (UEA-1) are
markers that distinguish mTEC subsets (147). Both K14 positive and UEA-1 binding mTECs
were present in the developing medullary regions of control thymi (Fig. 12G, I). However,
only exceedingly rare cells expressed either of these mTEC markers in the Foxn1Cre;R26iTbx/+
thymic lobes (Fig. 12H, J). Furthermore, the mutant TECs failed to express the nuclear
protein Aire (autoimmune regulator), which regulates transcription of tissue restricted
antigens and is a marker for mTEC maturation (Fig. 12J) (32, 148, 149). Claudin (Cldn) 3
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Figure 12. A small number of FOXN1-positive TECs are present in the center of
Foxn1Cre;R26iTbx1/+ fetal thymic lobes.
(A-J) Representative IHC stains of transverse sections from control and
Foxn1Cre;R26iTbx1/+ E14.5 or E15.5 thymic lobes show distinct patterns of TEC localization.
(A) FOXN1 positive (green) TECs are dispersed throughout the control thymus and TBX1
positive cells are not found. (B) The small number of FOXN1 positive TECs (green) in
Foxn1Cre;R26iTbx1/+ mutants localize to the center of each lobe and generally segregate
away from the abundant TBX1 positive TECs (red) that are concentrated in the outer region
of the each lobe. (C-F) Only a few of the mutant TECs are positive for β5t and CD205 that
mark the cTEC lineage (green), and these cells localize primarily in the center of each lobe
where FOXN1 positive cells are found (see Fig. 6B). (G-J) Markers of the mTEC lineage
(UEA-1, Aire and K14) are readily detectable in control thymic lobes but rarely present in
Foxn1Cre;R26iTbx1/+ lobes. Scale bars: 50 µm.
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Figure 12. A small number of FOXN1-positive TECs are present in the center of
Foxn1Cre;R26iTbx1/+ fetal thymic lobes.
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Figure 13. Thymocytes co-localize with TECs expressing low levels of FOXN1 in E17.5
Foxn1Cre;R26iTbx1/+ thymic lobes.
Representative IHC stains of serial transverse sections showing co-stains for FOXN1
and TBX1 (A,C) and for IKAROS and TBX1 (B,D) in control (A,C) and Foxn1Cre;R26iTbx1/+
(B,D) E17.5 thymic lobes.
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Figure 13. Thymocytes co-localize with TECs expressing low levels of FOXN1 in E17.5
Foxn1Cre;R26iTbx1/+ thymic lobes.
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and Cldn 4 are expressed on TEC precursors that are committed to the mTEC lineage (91).
There was a paucity of Cldn3/4 positive TECs in Foxn1Cre;R26iTbx/+ thymi (Fig. 12F).
Interestingly, the few Cldn3/4 positive precursors were positioned towards the outer region
of the thymic lobes where TECs expressing higher levels of TBX1 and lower levels of
FOXN1 are found. Taken together, these data suggest that ectopic TBX1 compromises
differentiation of both cTEC and mTEC lineages.

Ectopic TBX1 results in an accumulation of early TEC progenitors
PLET-1 is a cell surface protein expressed by founder cells in the 3rd pp that give rise
to both cTEC and mTEC lineages (87, 89, 90, 150, 151). A relatively high frequency of
TECs in both Foxn1Cre;R26iTbx/+ and control thymic rudiments express PLET-1 at E12.5 (Fig.
14A, B), consistent with previously published data (57). The frequency of PLET-1 positive
TECs decreases during ontogeny as TECs undergo differentiation and proliferation (57).
Thus, PLET-1 expression is confined to a rare subset of TECs in control thymi by E14.5
(Fig. 14C). In striking contrast, a higher frequency of PLET-1 positive cells persists at E14.5
in the Foxn1Cre;R26iTbx/+ thymi (Fig. 14D). Furthermore, the PLET-1 positive cells in the
mutant thymi are found in the outer region of the lobes, similar to the localization pattern
observed for TBX1 expressing cells (Fig. 14D). These data are consistent with ectopic
TBX1 expression blocking TEC differentiation at an early progenitor stage. Flow cytometric
analysis confirmed an increased frequency of PLET-1 positive cells in E15.5
Foxn1Cre;R26iTbx/+ compared to control thymi (Fig. 14E). However, the absolute number of
PLET-1 positive cells was comparable in Foxn1Cre;R26iTbx/+ and control thymi (Fig. 14F, G).
The maintenance of the same number of PLET-1 positive TECs in the hypoplastic
Foxn1Cre;R26iTbx/+ thymi at late stages of ontogeny is more consistent with TBX1 blocking
differentiation of existing progenitors, rather than reverting differentiated TECs to a
progenitor state.
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Figure 14. Foxn1Cre;R26iTbx1/+ fetal thymi contain a high frequency of TEC progenitors.
(A-D) Representative IHC stains of transverse sections from control and
Foxn1Cre;R26iTbx1/+ E12.5 or E14.5 thymic lobes showing Plet-1 (red) and K5 (green)
positive cells. Note the high frequency of Plet-1 positive TEC progenitors in the outer region
of Foxn1Cre;R26iTbx1/+ thymic lobes (D). Scale bars: 50 µm (E) FACS plots showing MHC II
and Plet-1 expression on EpCAM+ CD45- control and Foxn1Cre;R26iTbx1/+ TECs. Numbers
in each quadrant show percentage of cells. (F, G) Bar graphs showing the frequency (F) or
number (G) of Plet-1 positive cells in E14.5 control and Foxn1Cre;R26iTbx1/+ thymic lobes.
Data show mean ± SD for 4 control and 4 Foxn1Cre;R26iTbx1/+ thymic lobes. **P<0.001.
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Figure 14. Foxn1Cre;R26iTbx1/+ fetal thymi contain a high frequency of TEC progenitors.
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Thymocyte development and localization is altered in the Foxn1Cre;R26iTbx/+ thymic
microenvironment
TECs are required for thymocyte proliferation, survival and differentiation (152-155).
Given the profound arrest in TEC development resulting from ectopic Tbx1 expression, we
expected to find defects in thymocyte development. Total thymocyte cellularity was
decreased by ~5 fold in in E15.5 Foxn1Cre;R26iTbx/+ compared to control thymi (Fig. 15A).
Flow cytometric analyses were performed to assess thymocyte differentiation. At this
developmental stage, thymocytes have not yet differentiated beyond the immature CD4 and
CD8 double negative (DN) precursor subset (Fig. 15B). Expression of c-kit and CD25
distinguishes DN subsets at sequential maturation stages, referred to as DN1 through DN4.
Flow cytometric analysis revealed a partial block at the DN3 to DN4 transition in
Foxn1Cre;R26iTbx/+ thymi (Fig. 15C). The reduction in thymocyte cellularity, together with the
partial differentiation arrest at the DN3 stage suggest that the aberrant TEC
microenvironment in Foxn1Cre;R26iTbx/+ thymi fails to provide adequate growth and
differentiation signals to support normal thymocyte development. IHC analysis of E14.5
thymi revealed that thymocytes, identified by expression of the Ikaros transcription factor
(156), were distributed throughout the control thymic lobes (Fig. 15D). In contrast, the
scarce thymocytes present in Foxn1Cre;R26iTbx/+ fetal thymus lobes were concentrated in the
central region in juxtaposition to TECs expressing higher levels of FOXN1 (compare Figs.
12B and 15E). This spatial relationship emphasizes the importance of TEC-thymocyte
crosstalk in T cell development.
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Figure 15. Thymocyte localization, cellularity and development are aberrant in
Foxn1Cre;R26iTbx1/+ fetal thymi.
(A, B) Representative IHC stains of transverse sections from control and
Foxn1Cre;R26iTbx1/+ E15.5 thymic lobes show that thymocytes identified as Ikaros positive
(green) are scattered through control thymic lobes, but are restricted to the central region of
mutant lobes where FOXN1 positive cells are found (see Fig. 6B). Scale bars: 50µm. (C)
Bar graph of the number ± SD of thymocytes recovered from control (n = 2) and
Foxn1Cre;R26iTbx1/+ (n = 3). (D) FACS plots showing that most E15.5 thymocytes are CD4
or CD8 double negative (DN) cells. (E) FACS plots showing the distribution of DN subsets
based on c-kit and CD25 expression. Note the partial block at the DN3 (c-kit-CD25+) to DN4
(c-kit-CD25+) developmental transition in Foxn1Cre;R26iTbx1/+ thymocytes.
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Figure 15. Thymocyte localization, cellularity and development are aberrant in
Foxn1Cre;R26iTbx1/+ fetal thymi.
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CONCLUSIONS
The molecular events that specify thymus fate and regulate TEC development have
yet to be fully delineated. Previous reports suggested that TBX1 promotes thymus
development based on the thymic aplasia or hypoplasia in patients with 22q11.2 deletion
(DiGeorge) syndrome, in which loss or haploinsufficiency of Tbx1 is the primary defect (40,
114, 121, 136). However, the failure of pharyngeal pouch formation in Tbx1 deletion mutants
(112, 114, 115, 118, 119) suggests that the thymus phenotype in Tbx1 mutants is likely
secondary to defects in pharyngeal pouch formation and does not reflect a role for Tbx1 in
wildtype thymus organogenesis. Our current results clearly demonstrate that TBX1 can
suppress Foxn1 expression, preventing both TEC proliferation and differentiation. These
data, combined with the down regulation of Tbx1 in the ventral domain during pouch
formation (112, 121, 122), support the conclusion that TBX1 is a negative regulator of
thymus development.

Ectopic expression of TBX1 in ventral 3rd pp endoderm suppresses FOXN1
All of the defects in TEC maturation and proliferation observed in Foxn1Cre;R26iTbx/+
thymi are consistent with the suppression of Foxn1 expression, which is known to promote
these processes. Down regulation of Foxn1 occurred as early as E11.5, almost immediately
upon ectopic expression of Tbx1. The inverse pattern of FOXN1 and TBX1 protein levels in
E15.5 Foxn1Cre;R26iTbx/+ TECs is further evidence that TBX1 negatively regulates Foxn1
expression. TBX1 may shut down Foxn1 expression by an indirect rather than direct
mechanism, since there is not an obvious TBX binding site in the Foxn1 promoter (BLAT;
UCSC Genome Bioinformatics). These findings are consistent with the report of Bain, et al.
showing that ectopic activation of SHH signaling in 3rd pp endoderm both induces Tbx1
expression and represses Foxn1 (V.E.B. and N.R.M., unpublished).
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The few FOXN1 positive TECs present in these mutants appear to be the progeny of
3rd pp progenitors that failed to effectively express ectopic TBX1, as these cells have very
low or undetectable levels of TBX1. This failure could be due to inefficient or late deletion of
the stop codon in the R26iTbx1 allele, or due to secondary shutdown of the Rosa26 locus.
These FOXN1 positive cells tend to aggregate in the center of the lobe, forming a
microenvironment that supports differentiation of a small number of thymocytes, with
variable efficiency.

Ectopic TBX1 expression does not reverse thymus fate
By E11.5, most cells in the wildtype 3rd pp have acquired either a thymus or
parathyroid fate, and express either Foxn1 or Gcm2 (54). In contrast, the reduction of
FOXN1 positive cells in the Foxn1Cre;R26iTbx/+ 3rd pp, coupled with the lack of a
compensatory expansion of Gcm2 expression, results in a sizeable domain containing cells
that fail to express either marker. However, as Foxn1 is not required to establish thymus
fate, these cells could still retain thymus fate specification. This appears to be the case, as
these ventral cells do express IL7 and FOXG1, both of which are expressed by thymus fated
cells independently of Foxn1–mediated regulation (12, 108) and B.G. Condie, personal
communication). These data also demonstrate that ectopic Tbx1 cannot reverse thymus fate
after it is established, since Foxn1Cre is expressed in 3rd pp cells that are already committed
to a thymus fate. The down regulation of Tbx1 in the ventral domain during pouch outgrowth
at E9-9.5, prior to expression of thymus-specific markers, raises the possibility that this
down regulation is essential to establish thymus fate. Activation of R26iTbx1 in 3rd pp
endoderm at an earlier developmental stage will be required to test whether TBX1 can block
initial thymus fate commitment.
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Ectopic TBX1 expression arrests TEC differentiation at an early progenitor stage
TEC differentiation is arrested at a PLET-1 positive stage in Foxn1 null (nude)
mutants (88, 90). Plet-1 expressing TECs have been shown to contain a TEC progenitor
activity in transplant experiments at both early and later stages of fetal thymus development
(89, 150). These data strongly suggest that PLET-1 likely marks a very early stage of
committed thymus progenitor cells (reviewed in (106). The loss of FOXN1 in
Foxn1+/Cre;R26+/iTbx1 fetal thymi was associated with a marked increase in the frequency of
PLET-1 positive TECs. However, the number of PLET-1 positive TECs was comparable in
mutant and control fetal thymi. These data indicate that ectopic TBX1 results in arrested
differentiation of PLET-1 positive progenitors, rather than induction of their proliferation or
reversal of a differentiated phenotype to a progenitor-like state.

Ectopic TBX1 expression uncouples FOXN1 and MHC Class II expression
Previous studies have suggested that Foxn1 directly or (more likely) indirectly
regulates MHC Class II expression. MHC Class II levels are severely downregulated on
TECs from Foxn1Δ/Δ mutants (99, 157). Furthermore, a direct relationship was observed
between the frequency of MHC Class II positive TECs and Foxn1 levels in an allelic series
of strains expressing progressively lower levels of Foxn1 (57). Therefore, we were surprised
to find that the minor fraction of MHCIIhi Foxn1Cre;R26iTbx/+ TECs expressed exceedingly low
levels of Foxn1 mRNA. The mechanism responsible for this finding is not clear, but this
result does indicate that FOXN1 levels alone are not sufficient to determine MHC Class II
levels. It is possible that ectopic Tbx1 in Foxn1Cre;R26iTbx/+ mutants disrupts the normal
regulatory pathway linking Foxn1 and MHC Class II. Regardless of the mechanism, Foxn1
and MHC Class II expression are uncoupled by ectopic Tbx1 expression in TECs.
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Ectopic TBX1 expression does not induce GCM2 expression
GCM2 is a transcription factor that marks the parathyroid fated domain of the 3rd pp
and is required for parathyroid survival and differentiation (54, 121, 158). Tbx1 and Gcm2
expression domains overlap in the dorsal 3rd pp, and previous reports suggested that Gcm2
may be a downstream target of Tbx1, based on microarray data in Tbx1 null mutants (139),
or on the persistence if Tbx1 expression in Gcm2 null mutants (121). However, our data
show that ectopic expression of TBX1 was not sufficient to induce an expansion of Gcm2
expression into the ventral 3rd pp. This result is consistent with the finding that expression of
a constitutively active allele of Smo throughout the 3rd pp expanded the Tbx1 expression
domain ventrally, but did not expand Gcm2 expression (V.E.B. and N.R.M., unpublished).
Thus, activation of additional positive regulators and/or suppression of negative regulators
must be involved in regulating parathyroid fate specification and/or Gcm2 expression during
3rd pp patterning.

80

Chapter 4: The miR-17-92 cluster regulates Tbx1 expression in 3rd pharyngeal pouch
endoderm

INTRODUCTION
Factors that specify thymus versus PT fate have not yet been identified. Although
several labs have identified transcription factors within the endoderm or mesenchyme that
have temporal expression patterns consistent with a role in organ specification, these
candidates have not been shown to control thymus or PT fate. Thus, identifying factors that
establish thymus fate would facilitate in vitro and in vivo approaches to specify endoderm
progenitors to a TEC fate in order to generate or maintain a functional thymus.
The transcription factor, Tbx1, is an example of one such factor that is implicated in
3rd pp organ specification. At E10.5, Tbx1 is expressed in the PT-fated domain, but silenced
in the ventral, thymus-fated domain (112, 121, 122), suggesting that Tbx1 must be
suppressed during thymus organogenesis. We have shown that ectopic expression of the
Tbx1 allele in the ventral domain of the 3rd pp inhibits FOXN1 expression leading to a block
in TEC differentiation, resulting in severely hypoplastic thymus lobes that have an
accumulation of TEC progenitors (111). Therefore, we wanted to determine what
mechanisms must be present to downregulate Tbx1 in the ventral domain of the 3rd pp at
E10.5, thus permitting proper thymus organogenesis to occur.
Evidence from other labs suggests that BMP morphogens may also play a critical
role in establishing TEC fate and/or promoting TEC differentiation (80, 81, 83). Specifically,
loss of Bmp signaling in the 3rd pp endoderm and NC-derived mesenchyme results in a
delay in thymus and PT separation as well as incomplete migration of the thymic anlage
(81). Furthermore, transgenic expression of Noggin, a Bmp inhibitor, results in hypoplastic,
cystic thymic lobes (83). Interestingly, Bmp2 and Bmp4 promote differentiation of cardiac
progenitor cells by activating miR-17-92, which suppresses the expression of Tbx1 (82).
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Furthermore, an additional study has shown that TBX1 binds SMAD1 to suppress Bmp4
signaling, suggesting a regulatory loop (133). Based on these findings, we propose a model
pathway in which Bmp2/4 activates miR-17-92 expression, which in turn downregulates
Tbx1 in the 3rd pp (Fig.4). We hypothesize that this feedback loop is required for thymus fate
specification and/or TEC differentiation.
MicroRNAs (miRNAs) are highly conserved, short non-coding RNAs that posttranscriptionally modify gene expression (125). Through imperfect Watson Crick base
pairing, miRNAs are capable of silencing numerous genes by binding complementary seed
sequences in the 3’ UTR of target mRNA. Interestingly, miRNAs are differentially expressed
within tissues at specific times during development, thus adding additional complexity to
their roles throughout normal developmental and aging processes. While the cellular
functions of some miRNAs have been defined in T cell development (159), their role in
thymus organogenesis has yet to be defined. To address this, we have used both loss-offunction (LOF) and gain-of-function (GOF) genetic models to test the hypothesis that miR17-92 plays a role in suppressing Tbx1 expression in the developing 3rd pp endoderm to
promote thymus cell fate.

RESULTS
Expression of miR-17-92 family members in 3rd pp endoderm
The expression of miR-17-92 cluster members has been investigated in various
tissues (82, 130, 132, 160). However, the timing and expression pattern of miR-17-92 within
the 3rd pp endoderm has not yet been reported. Therefore, we first addressed this question
by using in situ hybridization (ISH). Given that miRNAs are approximately twenty-two
nucleotides in length and transiently expressed, this presents a unique challenge when
trying to define their expression pattern. We used miRNA in situ probes that employ locked
nucleic acid (LNA) technology (Exiqon), in which the sugar ring is locked in the 3’ endo
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conformation, significantly increasing the probe’s affinity for short, specific RNA sequences.
Based on reports studying the frequency at which each member is detected, we chose to
analyze the expression pattern of miR-17, miR-19a and miR-92a in wildtype 3rd pp
endoderm at E10.5 and E11.5.
Wildtype C57BL/6J embryos were harvested at each time point, processed for ISH
analysis and sectioned to obtain both 3rd pps in their entirety. Our preliminary data indicate
that at E10.5, miR-17 is detected in the dorsal domain of the 3rd pp as well as in the
surrounding mesenchyme (Fig.16A). However by E11.5, miR-17 is expressed in the ventral
domain of the 3rd pp, and is no longer detected in the dorsal domain as was seen at E10.5
(Fig.16F). Next, we analyzed the expression pattern of miR-19a within in the developing
endoderm. The expression pattern of miR-19a is different from that of miR-17 at E10.5, in
that it is expressed in the ventral region of the 3rd pp and is not detected in the mesenchyme
(Fig.16B). At E11.5, miR-19a is still expressed in the ventral domain, however not as highly
as was seen at E10.5 (Fig.16G). We also analyzed expression of miR-92a and found it to
be widely expressed throughout the 3rd pp endoderm and surrounding mesenchyme at
E10.5, but restricted to the ventral domain at E11.5 (Fig.16C,H). It is interesting to note that
miR-17-92 is not only detected in the 3rd pp endoderm, but also in the adjacent
mesenchyme. Given that Tbx1 is expressed in non-NC-derived mesenchyme (112) and that
the 3’UTR of Tbx1 contains miR-17-92 seed sequences (82), it is not surprising that
expression of this cluster is also detected in the mesenchyme.
Additionally, the Martin lab generated a miR-17-92-LacZ transgenic mouse line to
analyze the expression of pri-miR-17-92 during heart development (132). Although these
mice are no longer available, Dr. Martin kindly provided images of the E11.5 3rd pp from their
studies. In wildtype embryos, pri-miR-17-92-LacZ is expressed in the ventral domain of the
3rd pp (data not shown, personal communication). Furthermore, the miR-17-92 cluster is
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Figure 16. Expression of miR-17-92 family members in 3rd pp endoderm.
(A-J) ISH analysis of (A, F) miR-17, (B, G) miR-19a and (C, H) miR-92a expression
in the 3rd pp endoderm of C57BL/6J at (A-E) E10.5 and (F-J) E11.5. (D, I) Positive control is
Fgf8. (E, J) Negative control is a scrambled probe. Arrows indicate examples of miR signal.
v, ventral. d, dorsal. Scale Bars: 50 µm.
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also expressed in the mesenchyme adjacent to the ventral domain of the pouch and extends
towards the thymus-PT boundary. However, its expression does not reach completely into
the mesenchyme surrounding the dorsal domain.
Although preliminary, our results describing the expression pattern of miR-17, miR19a and miR-92a in wildtype 3rd pp endoderm are consistent with the results from the Martin
lab using the pri-miR-17-92-LacZ reporter line. Therefore, these results bolster the
conclusion that miR-17-92 is expressed in the developing 3rd pp endoderm and adjacent
mesenchyme.

Global deletion of miR-17-92 reduces the frequency of FOXN1 positive cells at E11.5
Based on our model shown in Figure 4, we predicted that global deletion of miR-1792 would result in an incomplete downregulation of Tbx1 in the 3rd pp, thus leading to an
increased frequency of TBX1 positive cells in the ventral domain of the 3rd pouch endoderm.
To test this prediction, we used miR-17-92Null embryos to determine if the absence of the
miR-17-92 cluster affects 3rd pp patterning and thus thymus organogenesis. Mice null for
miR-17-92 die shortly after birth and have craniofacial abnormalities, cardiac defects and
lung hypoplasia (161). We obtained miR-17-92Null embryos from the Martin lab at Baylor
College of Medicine and serial sagittal sections from control and miR-17-92Null embryos were
cut for IHC analysis of region-specific markers throughout the pouch.
Given our evidence that Tbx1 regulates Foxn1 expression (111) and the finding that
miR-17-92 downregulates Tbx1 in cardiac progenitors during cardiomyocyte differentiation
(132), we hypothesized that TBX1 expression would be increased in the 3rd pp of miR-1792Null mice. Not surprisingly, we observed an increase in the TBX1 expression domain that
expanded towards the ventral region of the 3rd pp, whereas it remained restricted to the
dorsal domain in the control (Fig.17). Although TBX1 was ectopically located in the 3rd
pouch, it was not detected throughout the endoderm into the ventral tip as was seen in the
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Figure 17. Global deletion of miR-17-92 reduces the frequency of FOXN1 positive cells
at E11.5.
(A-D) Representative IHC stains of sagittal sections from 3rd pp of miR-17-92Null and
control E11.5 embryos. (A, B) Loss of miR-17-92 expression does not affect the
localization or frequency of GCM2 positive cells (red). (C-D) TBX1 (red) is restricted to the
dorsal, parathyroid-fated domain of the control, but is moderately expanded into the ventral
domain of the miR-17-92Null 3rd pp. (B, D) Note the reduction in FOXN1 positive cells (green)
and the absence of cells that are FOXN, GCM2 or TBX1 positive (yellow arrows) in the miR17-92Null 3rd pp. v, ventral. d, dorsal. Scale Bars: 50 µm.
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Foxn1Cre;R26iTbx/+ model (Fig.17C,D). This suggests that while miR-17-92 plays a role in
regulating Tbx1 expression, additional mechanisms are necessary to suppress its
expression in the ventral domain of the 3rd pp. Furthermore, we noted an increase in the
mesenchymal staining intensity of TBX1 surrounding the mutant 3rd pouch when compared
to littermate controls (Fig.17C-D), indicating that miR-17-92 may also function to regulate
TBX1 in non-endodermal-derived tissues. Furthermore, despite global deletion of the miR17-92 cluster, the 3rd pp developed and was similar in size to miR-17-92 sufficient littermate
controls (Fig.17). Interestingly, FOXN1 expression was downregulated in the mutant 3rd pp
at E11.5 (Fig.17B,D). Therefore, this result is consistent with our model that TBX1 indirectly
regulates the expression of FOXN1 in the ventral domain of the 3rd pp endoerm.
The transcription factor GCM2 is required for the differentiation of PT fated cells and
is expressed in the dorsal domain of the 3rd pp at E11.5 (54, 121). It has been suggested
that Tbx1 regulates Gcm2 expression because mice lacking Tbx1 fail to express Gcm2
(139). Furthermore, since Tbx1 expression is not altered in Gcm2-/- mice, Gcm2 is thought
to be a downstream target of Tbx1 (121, 139). Based on these data, we would expect
GCM2 expression to phenocopy that of TBX1 in the miR-17-92Null embryos. However,
GCM2 expression was unaltered in the mutant embryos at E11.5 when compared to control
littermates, suggesting that Gcm2 may not be a direct downstream target of Tbx1. These
data seemingly contradict the conclusion from gene expression studies in Tbx1 null mice
(139). However, given that pharyngeal segmentation does not occur in the absence of Tbx1,
the loss of Gcm2 expression in Tbx1 null mice is likely secondary to the absence of 3rd pp
formation.
By E11.5, the wildtype 3rd pp is patterned into distinct regions of FOXN1 positive
thymus-fated cells and TBX1/GCM2 positive PT-fated cells. At this stage of development,
organ fate has been specified in most 3rd pp cells and there are very few, if any, organspecific cells that comingle at the boundary between the thymus and PT fated cells.
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However, in the miR-17-92Null 3rd pp, there was not a clear demarcation between the thymus
and PT boundary, with several thymus- or PT-specific cells comingling (Fig.17).
Furthermore, when miR-17-92 is globally deleted, there are a number of cells at the thymusPT boundary that do not express FOXN1, GCM2 or TBX1 (yellow arrows), suggesting that
organ-specific cell fate is delayed or defective or that there may be a reversal in cell identity.
These results suggest that global deletion of miR-17-92 increases the TBX1
expression domain into the ventral region of the 3rd pp and reduces FOXN1 expression.
Furthermore, the absence of miR-17-92 results in a small population of cells that
presumably, have yet to assume organ-specific fate given that they do not express either
thymus- or PT-specific markers. Taken together, these data support our model in which
miR-17-92 mediates downregulation of Tbx1 in the 3rd pp. These data also demonstrate a
role for miR-17-92 in regulating Tbx1 expression in mesenchyme adjacent to the 3rd pp.

Global deletion of miR-17-92 impairs thymus organogenesis
Given that Foxn1 is required for TEC proliferation and differentiation (57, 87, 88, 99,
142), we hypothesized that thymus development would be inhibited as a result of the
reduced frequency of FOXN1 positive cells seen at E11.5 in the miR-17-92Null embryos. To
test this premise, we analyzed the location of thymic lobes as well as TEC differentiation in
E14.5 miR-17-92Null and littermate control embryos. The left thymic lobe was absent in the
first miR-17-92Null embryo we examined (Fig.18B). However, the right thymic lobe was
present, but severely ectopic, being located 60µm beneath the jaw and adjacent to the
thyroid. In addition, the right lobe was extremely hypoplastic when compared to the control.
It has been shown that during mouse embryogenesis, there is left-right asymmetry, with the
right side having the developmental advantage (81). Specifically, the 3rd pp on the right side
of the animal is larger than the left and separates from the pharynx prior to the left 3rd pp
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Figure 18. Global deletion of miR-17-92 impairs thymus organogenesis.
(A-F) Representative IHC stains of transverse sections from control and miR-1792Null E14.5 thymic lobes show that the absence of miR-17-92 results in an ectopic and
hypoplastic thymus phenotype. (A,B) 10X image demonstrates miR-17-92Null left thymic lobe
is absent (as indicated by an asterisk) and the right thymic lobe is severely ectopic and
hypoplastic as compared to the control. (C,D) FOXN1 positive cells are present in both the
miR-17-92Null and control thymic lobes. (E, F) TEC differentiation is not altered in the miR17-92Null thymic lobe as reflected by K8 expression in cortical TECs and K5 expression in
medullary TECs. Oe, oesophagus. Tr, trachea. Lx, larynx. Th, thyroid. Scale Bars: 50 µm.
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(80, 81, 162). This slight difference in developmental timing during normal organogenesis
may be exacerbated in the absence of miR-17-92, thus contributing to the phenotype we are
observing at E14.5 in miR-17-92Null embryos. However, it will be necessary to analyze
additional null mutants to reach a conclusion on this point.
The reduced expression of FOXN1 at E11.5 may contribute to the hypoplastic thymic
phenotype, given that it is required for TEC proliferation (57, 87, 88, 99, 142). However,
FOXN1 was expressed throughout the right lobe at levels comparable to that of the control
littermate (Fig.18A-B,C-D), suggesting that the few FOXN1 positive cells present in the 3rd
pouch were capable of proliferation. Next, we wanted to determine if TBX1 was ectopically
expressed in the E14.5 right lobe given that its expression persists in cardiomyocytes in the
absence of miR-17-92 (82). Despite the loss of miR-17-92, TBX1 expression was not
detected in the mutant lobe, but was apparent in the thyroid (Fig.18B,D). This further
supports the premise that additional mechanisms regulate Tbx1 expression at E10.5 in the
3rd pp endoderm.
To determine whether or not TEC differentiation was altered in the ectopic,
hypoplastic lobe, we analyzed the expression pattern of cytokeratins used to identify TEC
sublineages. The miR-17-92Null right thymic lobe had distinct cortical and proto-medullary
regions as reflected by the expression of K8 and K5, respectively (Fig.18E-F). These results
are not surprising given that FOXN1 was expressed throughout the lobe and is required for
TEC maturation. Taken together, these preliminary results indicate that miR-17-92 is
required for proper thymus organogenesis and migration.
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Targeted deletion of miR-17-92 in TECs affects expression of TBX1 in the 3rd pp
endoderm and surrounding mesenchyme
Our data suggest that global deletion of miR-17-92; 1) expands Tbx1 expression into
the ventral, thymus-fated domain, 2) reduces the frequency of Foxn1 expressing cells in the
E11.5 3rd pp endoderm and 3) does not affect GCM2 expression (Fig.17). These results are
consistent with our hypothesis proposing that miR-17-92 suppresses Tbx1 expression in the
ventral domain of the 3rd pp (Fig.4). Furthermore, as our model predicts, the altered 3rd pp
patterning with respect to FOXN1 and GCM2 in miR-17-92 null embryos is similar to that
obtained in the Foxn1Cre/+;R26iTbx/+ 3rd pp. However, a caveat to these results is that global
deletion of the miR-17-92 cluster in non-endodermal tissues, such as mesenchyme, may be
at least partly responsible for the altered 3rd pp phenotype. Therefore, to further define the
role of miR-17-92-mediated regulation of Tbx1 in the 3rd pp, we employed a LOF model to
site-specifically delete miR-17-92 in TECs. Specifically, miR-17-92Fl/Fl female mice were
crossed with Foxn1Cre males to delete expression of the miR cluster at ~E11.25 in thymusfated cells of the 3rd pp endoderm.
Embryos were harvested at E11.5 and sagittal sections were obtained to determine
whether Foxn1Cre-mediated deletion of miR-17-92 alters 3rd pp development and expression
of region-specific markers including Tbx1, Foxn1, and Foxg1. There was not a noticeable
difference in 3rd pp size between control and Foxn1Cre/+;miR-17-92Fl/Fl embryos. Interestingly,
while TBX1 expression was restricted to the dorsal, PT-fated domain of the mutant 3rd
pouch, the staining intensity appeared greater than that in the control (Fig.19A-B).
Additionally, not only did we notice this increase in staining intensity in the endoderm, but
also in the mesenchyme surrounding the mutant pouch (Fig.19A-B). Taken together, these
data suggest that TEC expression of miR-17-92 regulates TBX1 in regions adjacent to the
ventral domain of the 3rd pp.
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Figure 19. Targeted deletion of miR-17-92 in TECs affects expression of TBX1 in the
3rd pp endoderm and surrounding mesenchyme.
(A-D) Representative IHC stains of sagittal sections of 3rd pp from control and
Foxn1Cre/+; miRNA-17-92Fl/Fl embryos at E11.5. Foxn1Cre-mediated excision of miR-17-92
specifically deletes expression of the miRNA cluster from thymus-fated cells at E11.5. (A-B)
TBX1 expression (red) is not expanded into the ventral region of Foxn1Cre/+; miRNA-17-92Fl/Fl
3rd pp as compared to control. However, there are a significant number of cells that coexpress FOXN1 and TBX1 at the thymus and PT boundary (yellow arrows). (C-D) FOXG1
expression (red) is restricted to the ventral domain of the 3rd pp pouch. Note the FOXG1
positive, FOXN1 negative cells at the thymus, PT boundary (yellow arrows). v, ventral. d,
dorsal. Scale Bars: 50 µm.
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Figure 19. Targeted deletion of miR-17-92 in TECs affects expression of TBX1 in the
3rd pp endoderm and surrounding mesenchyme.
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Since Foxn1Cre is not expressed until ~E11.25, it is not surprising that we did not
observe a discernable difference in the frequency of FOXN1 positive cells among mutant
offspring and somite-matched control littermates at E11.5 (Fig.19A-B). However, we did
observe that the mutant pouch contained cells at the thymus-PT boundary that coexpressed FOXN1 and TBX1 (Fig.19B, yellow arrows). Such co-expressing cells are
exceedingly rare in the E11.5 wildtype pouch (Fig.19A). This is interesting to note, as cells
located at the thymus-PT boundary are the last to assume either organ-specific fate (51, 54,
111). These results suggest that deleting miR-17-92 in cells at the thymus-PT boundary
that have yet to fully commit to a thymus fate, prevents TBX1 downregulation, thus
permitting co-expression of TBX1 and FOXN1. Also, given the fact that we are deleting
expression of the miR cluster in Foxn1Cre-specific endoderm, it is interesting to note that we
are observing effects in TBX1 expression in the dorsal domain of the 3rd pp and surrounding
mesenchyme.
We also analyzed expression of the transcription factor FOXG1 in the E11.5 3rd pp
from mutant and control embryos. Foxg1 is expressed in discrete regions of wildtype 3rd pp
endoderm and is co-expressed with FOXN1 by TECs at late fetal and postnatal stages
(108). Importantly, Foxg1 is expressed in the 3rd pp prior to, and independent of Foxn1 (Wei
and Condie, unpublished data). Furthermore, we previously showed that FOXG1 is
expressed in FOXN1 negative cells of the ventral 3rd pp in E11.5 Foxn1Cre/+; R26iTbx/+
embryos indicating that thymus cell fate is not altered in the presence of ectopic Tbx1 (111).
Similarly, we found abundant expression of FOXG1 in the 3rd pp of mutant embryos
(Fig.19D). Furthermore, we identified a small population of cells within the ventral domain of
the mutant 3rd pp that were FOXG1+FOXN1Neg-Low, with the majority of those cells being
located at the thymus-PT boundary (Fig.19D, yellow arrows). This suggests that the cells
co-expressing FOXN1 and TBX1 at that the thymus-PT boundary are likely to also express
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the thymus-specific marker FOXG1, supporting the notion that they are committed to the
thymus cell lineage.

TBX1 positive cells persist in the anterior portion of Foxn1Cre/+; miR-17-92Fl/Fl thymic
lobes
To determine if targeted deletion of miR-17-92 in TEC progenitors alters TEC
differentiation, Foxn1Cre/+;miR-17-92Fl/Fl and control embryos were harvested at multiple
stages throughout late fetal development. Serial transverse sections were obtained
throughout the entirety of each lobe and analyzed for expression of various progenitor or
lineage specific TEC markers. Unlike the thymic hypoplasia and ectopia observed in miR17-92Null embryos, Foxn1Cre/+;miR-17-92Fl/Fl thymi are comparable in size and location to that
of control embryos at E12.5, E14.5 and E17.5 and express similar levels of FOXN1 (Fig.20).
This result is not surprising given that FOXN1 was widely expressed throughout the ventral
domain of the mutant 3rd pp and that Foxn1 is required for TEC differentiation and
proliferation.
However, because there were cells in the E11.5 3rd pp that co-expressed FOXN1
and TBX1, we asked whether TBX1 is expressed in the mutant TECs at later developmental
stages. Considering that Tbx1 is not expressed in fetal or adult wildtype TECs (111, 122,
163) and that Tbx1 expression does not extend into the ventral domain of the mutant 3rd pp,
we expected very few, if any, TECs to co-express FOXN1 and TBX1. Indeed, we did not
observe FOXN1 positive TECs in control thymi that co-expressed TBX1 (Fig.20A).
Interestingly however, we found a rare subset of TECs in the most anterior region of the
mutant lobes that expressed TBX1, but no (or extremely low levels) of FOXN1 at E12.5 (Fig.
20B, yellow arrows). Notably, the ectopic expression of TBX1 in the anterior portion of the
thymic lobes persisted at E14.5 and E17.5 in the mutant embryos (Fig.20D,F, yellow
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Figure 20. TBX1 positive cells persist in the anterior portion of Foxn1Cre/+; miR-1792Fl/Fl thymic lobes
(A-F) Representative IHC stains of transverse sections from (A, B) E12.5, (C, D)
E14.5 and (E, F) E17.5 control and Foxn1Cre/+;miRNA-17-92Fl/Fl thymic lobes. (B, D, E) Note
the TBX1 positive (red), FOXN1 negative to low cells in the anterior portion of the Foxn1Cre/+;
miRNA-17-92Fl/Fl thymic lobe (yellow arrows). (A, C, E) FOXN1 and TBX1 co-expressing
cells are not present in the control. Scale bars: 50 µm.
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arrows). Furthermore, as was seen at E12.5, the TBX1 positive cells also expressed
negative to low levels of FOXN1 (Fig.20D,F). Taken together, these data suggest that the
miR-17-92 cluster might not only be important in downregulating Tbx1 at E10.5 in the ventral
domain of the 3rd pp, but may play a role in maintaining continuous suppression of Tbx1 in
TECs at later stages during development.
The frequency and location of the FOXN1/TBX1 co-expressing cells within the
mutant thymus at multiple stages of fetal development provides insight into what might be
occurring in the Foxn1Cre/+;miR-17-92Fl/Fl E11.5 pouch. The 3rd pp is oriented in such a way
that the dorsal domain is anterior to that of the ventral domain. When the thymus and PT
separate from one another and the thymus migrates to a more posterior location, those cells
located at the boundary will presumably be located in the anterior region of the thymus lobe.
Therefore, this suggests that the FOXN1Neg-LowTBX1+ cells located at the thymus-PT
boundary in the E11.5 3rd pp persist in the mutant fetal thymus lobes. Taken together, these
results support the hypothesis that miR-17-92 plays an important, but not indispensable role
in extinguishing Tbx1 expression in Foxn1 positive cells.

Foxn1Cre/+; miR-17-92Fl/Fl fetal thymi contain a rare population of TECs that co-express
TBX1, PLET1 and low levels of FOXN1
The persistence of FOXN1Neg-LowTBX1+ cells from E11.5 in the Foxn1Cre/+;miR-1792Fl/Fl 3rd pp into the fetal thymic lobes at E17.5 may be attributable to one of the following;
1) cells at the thymus-PT boundary have committed to a thymus fate but are arrested at a
progenitor-like state or 2) thymus cell fate has been reversed and TBX1 is downregulating
FOXN1 to promote the establishment of PT fate. The first possibility is supported by our
work using the Foxn1Cre/+;R26iTbx1/+ model in which ectopic expression of Tbx1 in Foxn1
positive cells results in an early arrest in TEC differentiation (111). Therefore, we predicted
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that TEC maturation would be blocked when miR-17-92 is deleted in Foxn1 positive cells
and TBX1 is ectopically expressed. To test this hypothesis, serial sections were taken at
E14.5 and stained with either GCM2 (to determine if cell fate was reversed), PLET-1 (to
determine if the cells were arrested in a bipotent TEC progenitor state) or with ΔNp63
(expressed by endodermal-derived cells).
Interestingly, the FOXN1Neg-LowTBX1+ cells are negative for GCM2 indicating that this
rare population did not assume a PT cell fate. Furthermore, these cells tend to organize
around regions devoid of thymic epithelium (TE). Studies are currently underway to identify
what these cells are and if they provide a specialized niche that attracts this rare group of
cells. Although the cells within the thymus did not express GCM2, the data show that there
are a few GCM2 positive cells in close proximity to the mutant thymic lobe (Fig. 21B-C).
This is not uncommon given that when the thymus and PT separate from one another during
organogenesis, a few PT cells are often left behind and can be detected in proximity to the
thymic lobes (164).
ΔNp63, an isoform of p63, is a target of FOXN1 and has been shown to regulate cell
cycle progression and differentiation in TECs (100, 165). In the control, ΔNp63 is coexpressed with FOXN1 at relatively comparable levels throughout the thymus (Fig. 21D).
Similar to that in the control, ΔNp63 was co-expressed with FOXN1 in the E14.5 mutant
thymus, but at higher levels than that of FOXN1 (Fig. 21D-F). In addition, the FOXN1LowNeg

TBX1+ cells present in the mutant thymus were also ΔNp63 positive (Fig. 21E-F),

providing evidence that this rare population of cells is of endodermal origin. However, these
results do not determine if these cells are committed to the TEC lineage, but are blocked at
an early progenitor stage. To resolve this question we analyzed Plet-1 expression. Plet-1
identifies bipotent TEC precursors that are capable of differentiating into both cortical and
medullary lineages (90). Initially Plet-1 is widely detected in TEC progenitors, and as
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Figure 21. Foxn1Cre/+; miRNA-17-92Fl/Fl fetal thymi contain a rare population of TECs
that co-express TBX1, PLET1 and low levels of FOXN1.
(A-I) Representative IHC stains of transverse sections from E14.5 control and
Foxn1Cre/+; miRNA-17-92Fl/Fl thymi. To determine the identity of the TBX1 positive cells in
anterior portion of the Foxn1Cre/+; miRNA-17-92Fl/Fl fetal thymus, serial sections were stained
with the (A-C) parathyroid marker GCM2 (red) and TEC progenitor markers (D-F) ΔNp63
(red) and (G-I) PLET1 (turquoise). (B, C, E, F) Note the few GCM2 positive cells in the
anterior potion of the Foxn1Cre/+; miRNA-17-92Fl/Fl lobe. It is common for a few parathyroid
cells to be attached to the thymus after the thymus and parathyroid separate earlier in
development. The TBX1 positive cells in fetal Foxn1Cre/+; miRNA-17-92Fl/Fl thymi are GCM2
negative, but are positive for the TEC progenitor markers (E,F,H,I) ΔNp63 and PLET1.
Scale bars: 50 µm.
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Figure 21. Foxn1Cre/+; miRNA-17-92Fl/Fl fetal thymi contain a rare population of TECs
that co-express TBX1, PLET1 and low levels of FOXN1.
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thymus development progresses the frequency of Plet-1+ TECs is reduced and Plet-1+ cells
become restricted to the medullary region (90). At E14.5, PLET-1 expression is detected in
a small population of mTECs in the control thymus (Fig. 21A,D,G). In contrast, Plet-1+ cells
are concentrated around the anterior region of the mutant lobe. Furthermore, the FOXN1NegLow

TBX1+ cells in the mutant thymus co-stain for Plet-1 (Fig.21I). This striking phenotype

suggests that deletion of miR-17-92 in Foxn1 positive cells causes an arrest in TEC
differentiation at an early progenitor state. These data support our hypothesis that miR-1792 mediated downregulation of Tbx1 is necessary to allow for proper TEC differentiation.
Transgenic expression of miR-17-92 downregulates TBX1, but not GCM2
We started preliminary experiments using a GOF model to further analyze the role of
miR-17-92-mediated regulation of Tbx1 in the 3rd pp and the fetal thymus. We obtained mice
in which an inducible miR-17-92OE allele was inserted into the Rosa26 locus and used
Foxn1Cre to express the miR-17-92 cluster in TECs. Since Foxn1 is expressed in the 3rd pp at
~E11.25 (54), we analyzed serial sections of E11.75 embryos for the expression of FOXN1,
TBX1 and GCM2 to determine if expression of the miR-17-92 transgene in Foxn1
expressing cells results in an expansion of thymus cell fate into the dorsal domain of the
pouch, at the expense of PT fate.
We hypothesized that overall pouch patterning would not be greatly affected in the
3rd pp of Foxn1Cre/+;miR-17-92OE/+ embryos given that miR-17-92 was likely to be
overexpressed in the ventral Foxn1 expressing domain that presumably has already
downregulated Tbx1. As expected, TBX1 was restricted to and expressed throughout the
dorsal domain of the mutant pouch (Fig.22). However, the staining intensity of TBX1 was
markedly reduced when compared to the control, where the staining intensity of TBX1 was
readily detectable (Fig.22B). Assuming that Foxn1Cre induces expression of the miR-17-92
transgene in the ventral, and not the dorsal, domain of the 3rd pp, this result is quite
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Figure 22. Transgenic expression of miR-17-92 downregulates TBX1, but not GCM2.
(A-D) Representative IHC stains of sagittal sections from 3rd pp of Foxn1Cre/+; miR17-92OE/+ and control E11.5 embryos. (A-B) TBX1 (red) is restricted to, and expressed
throughout the dorsal, parathyroid-fated domain of the Foxn1Cre/+; miR-17-92OE/+, 3rd pp
endoderm, but at significantly reduced levels when compared to the control. (C-D)
Overexpression of miR-17-92 does not affect the localization or frequency of GCM2 positive
cells (red). v, ventral. d, dorsal. Scale Bars: 50 µm.

106

Figure 22. Transgenic expression of miR-17-92 downregulates TBX1, but not GCM2.
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unexpected. Furthermore, we also observed a reduction in TBX1 positive cells in the
mesenchyme surrounding the mutant 3rd pp when compared to the control (Fig.22A,B).
Therefore, these data suggest that miR-17-92 may function to regulate Tbx1 expression in a
non-cell autonomous manner given that TBX1 expression is reduced in tissues where the
miR-17-92 transgene should not be expressed. However, analysis of miR-17-92 transgene
expression is required to clarify these findings.
When expression of FOXN1 and GCM2 were analyzed, there was not a discernable
difference in the overall patterning of the pouch. Expression of FOXN1 was restricted to the
ventral domain of the mutant 3rd pp and did not expand into the dorsal domain (Fig.22B,D).
In addition, GCM2 expression was not affected and remained restricted to the dorsal domain
in both the control and mutant pouches (Fig.22C,D). Taken together, these data suggest
that transgenic expression of miR-17-92 does not change the frequency of cells fated to
either a thymus or PT lineage. However, they do strongly support our model that miR-17-92
directly targets Tbx1 in the 3rd pp endoderm.

Expression of a miR-17-92 transgene in TECs does not affect their differentiation
Given that FOXN1 expression was not reduced and remained restricted to the
ventral domain of the 3rd pp when miR-17-92 was overexpressed, we did not expect to see a
difference in thymus size or TEC differentiation at later fetal stages. As anticipated, E14.5
Foxn1Cre/+;miR-17-92OE/+ thymi were comparable in size to that of the controls and were
located just anterior to the heart (Fig.23). Furthermore, FOXN1 positive cells were detected
throughout the control and mutant thymus lobes at comparable frequencies and staining
intensities (Fig.23).
To determine if overexpression of the miR-17-92 cluster alters the frequency of TECs
committed to either cTEC or mTEC lineages, we analyzed the FOXN1-dependent cTEC
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Figure 23. Transgenic expression of miR-17-92 does not affect TEC differentiation.
(A-F) Representative IHC stains of transverse sections from E14.5 control and
Foxn1Cre/+; miR-17-92OE/+ thymi. To determine if transgenic expression of miR-17-92 in
Foxn1 positive cells affects TEC commitment to either a medullary or cortical lineage, serial
sections were stained with (A-B) TEC marker FOXN1 (green) and mTEC marker UEA-1
(turquoise), (C-D) early mTEC marker Cldn3/4 (red) and early cTEC cell surface molecule
CD205 (turquoise), (E-F) bipotent TEC progenitor marker Plet-1 (turquoise) and
thymoproteosome subunit β5t (red). Note the mild increase in UEA-1 and Cldn3/4 along
with expanded protomedullary regions expressing Plet-1. Scale bars: 50 µm.
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Figure 23. Transgenic expression of miR-17-92 does not affect TEC differentiation.
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markers β5t and CD205 (92, 144, 146), mTEC markers UEA-1 and Cldn3/4 (147) and the
bi-potent progenitor marker Plet-1(90). In wildtype mice, β5t and CD205 are expressed at
early stages of cTEC differentiation, and are expressed by the vast the majority of mature
cTECs (Fig.23C,E). Expression of β5t and CD205 were comparable in mutant and control
thymi (Fig.23C-F), suggesting that early differentiation of the cTEC lineage is not altered
when miR-17-92 is overexpressed in Foxn1 positive cells. Both UEA-1 and Cldn3/4 are
expressed within the protomedullary regions of the E14.5 thymus (Fig.23A) as well as by
mature mTECs (91). Interestingly, expression of Cldn3/4 and UEA-1 appeared to be
increased in the proto-medullary regions of mutant thymi (Fig.23B,D).
Given the moderate increase in early mTEC-specific markers, we wanted to
determine if there was a change in frequency of Plet-1 positive TEC progenitor cells. As
expected, Plet-1 positive cells were detected in the proto-medullary regions of the control
and mutant E14.5 thymus (Fig.23E,F). However, the medullary regions in the mutant
thymus appear larger than those in the control and there is a concomitant increase in Plet-1
expression (Fig.23E,F). Taken together, these data suggest that transgenic expression of
miR-17-92 in TECs increases the frequency of Plet-1 positive cells and may skew TEC
differentiation to the medullary lineage.

CONCLUSIONS
We have reported that Tbx1 is a negative regulator of thymus development and must
be downregulated in the ventral, thymus-fated domain of the 3rd pp to allow for TEC
proliferation and differentiation (111). However, the molecular mechanisms that regulate
Tbx1 expression in the 3rd pp endoderm during thymus organogenesis remain to be defined.
During cardiac development, Tbx1 maintains cardiomyocytes in a progenitor-like state and
is downregulated via a Bmp2/4-miR-17-92-mediated mechanism to promote cell
differentiation (82). Given that Bmp4 promotes the identification and differentiation of TECs,
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and ectopic expression of Tbx1 arrests TEC differentiation (81, 111), we hypothesized that a
similar mechanism may regulate Tbx1 in the 3rd pp, as shown in Figure 4. Through the use
of miR-17-92 LOF and GOF models, our results demonstrate that miR-17-92 regulates Tbx1
and influences patterning in the 3rd pp endoderm.

The mir-17-92 cluster is expressed in the 3rd pp endoderm and surrounding mesenchyme
Prior to our studies, the expression pattern of miR-17-92 has never been defined in
the 3rd pp endoderm. Using LNA probes to miR-17, miR-19a and miR-92a, we
demonstrated that all three members of the miR-17-92 cluster are expressed in the 3rd pp
endoderm as well as in the adjacent mesenchyme. Although none of the miRNAs that were
analyzed had the same expression pattern within the 3rd pouch, the difference among each
individual miRNA might be attributable to the fact that each member of the miR-17-92
cluster behaves differently within different tissues, at different times during development
(reviewed in (130)). Furthermore, these data indicate that at E10.5, miR-17, miR-19a and
miR-92a are acting not only in the ventral domain, but also the dorsal region of the pouch,
suggesting that they may be functioning to temper expression of Tbx1. The continued
expression of miR-17, miR-19a and miR-92a in the ventral domain of the 3rd pp at E11.5
also suggests that miR-17-92 might serve as a mechanism to continuously suppress Tbx1
within the thymus-fated domain of the pouch.

Global deletion of miR-17-92 reduces FOXN1 expression in the 3rd pp and impairs thymus
organogenesis and migration
Global deletion of miR-17-92 resulted in an expansion of TBX1 expression into the
ventral domain of the 3rd pp. However, unlike the Foxn1Cre/+;R26iTbx1/+ mouse model, TBX1
was not detected in the ventral tip of the pouch. The fact that loss of miR-17-92 did not alter
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TBX1 expression to the same extent as ectopic expression in the Foxn1Cre/+;R26iTbx1/+ mouse
model is not surprising. First, Tbx1 was being driven from the strong R26 promoter.
Secondly, we know that miRNAs often have relatively minor effects on expression of their
target genes. Therefore, the fact that TBX1 was not as robustly expressed suggests that
additional mechanisms are in place to suppress Tbx1 in this region of the pouch.
However, the observed increase in TBX1 did result in fewer FOXN1 positive cells
located within the ventral domain of the 3rd pp. Furthermore, loss of miR-17-92 did not have
a detectable effect on GCM2 expression, which remained restricted to the dorsal domain.
These data suggest that additional mechanisms regulate Gcm2 expression in the pouch,
further supporting the notion that Tbx1 may not be directly upstream of Gmc2.
When analyzed at E14.5, one lobe of the null thymus was ectopic and hypoplastic
and the second lobe was not detected within the thoracic cavity or neck region. Although
the phenotype we observed at E14.5 was unexpected, the presence of the right lobe and
absence of the left could be explained by developmental asymmetry. As previously
discussed, the right side of the embryo tends to have a developmental advantage over the
left, with the right thymus lobe being larger and separating from the pharynx prior to that of
the left (80, 81, 162). Therefore, this difference in developmental timing could be amplified
in the absence of miR-17-92. Given that we observed an ectopic thymus lobe, miR-17-92
may also function to regulate thymus migration.
Interestingly, TEC differentiation was unaffected in the mutant lobe as FOXN1 was
widely expressed by TECs, suggesting that the few FOXN1 positive cells present at E11.5
were capable of proliferation and differentiation. Taken together, these results support our
hypothesis that miR-17-92 regulates Tbx1 in the developing 3rd pp and is therefore required
for proper thymus organogenesis.
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Deletion of miR-17-92 in TECs results in higher levels and ectopic expression of TBX1
Site-specific deletion of miR-17-92 in TECs using Foxn1Cre does not affect overall
patterning in the 3rd pp endoderm. FOXN1, GCM2 and TBX1 are restricted to, and
expressed in their respective domains. Interestingly, although the TBX1 expression domain
is not expanded in the absence of miR-17-92 at E11.5, its staining intensity is higher in the
dorsal domain as well as in the mesenchyme surrounding the mutant pouch than it is in the
control. This suggests that TEC expression of miR-17-92 may regulate expression of Tbx1
not only in the ventral domain of the pouch, but also in PT-fated and mesenchymal cells.
Furthermore, we find a rare population of cells located at the thymus-PT boundary in
the mutant 3rd pp endoderm that co-express FOXN1 and TBX1. This rare population of
Foxn1Neg-LowTBX1+ cells persists in anterior region of E12.5, E14.5 and E17.5 fetal thymus
lobes, and they express the bi-potent TEC progenitor marker Plet-1.
These data strongly support the notion that miR-17-92-mediated deletion of Tbx1 in
TECs that have not yet fully committed to the thymus lineage abrogates TEC differentiation
and arrests endodermal cells at a progenitor stage.

Transgenic expression of miR-17-92 in TECs non-cell autonomously regulates Tbx1
Although we have yet to perform experiments confirming that miR-17-92 is being
overexpressed in the ventral domain of the 3rd pp, based on numerous studies showing that
Foxn1Cre is expressed in ventral pouch and later in TECs, we anticipated that when miR-1792OE mice were crossed with Foxn1Cre mice, the miR cluster would be expressed in these
cell types. Therefore, based on the assumption that we were overexpressing miR-17-92 in
a region where Tbx1 was already downregulated, we hypothesized that the thymus-fated
domain would remain restricted to the ventral domain and not expand at the expense of the
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PT-fated domain. Our results support this hypothesis as FOXN1 and GCM2 expression was
not altered in the 3rd pp of Foxn1Cre/+;miR-17-92OE/+ embryos.
Interestingly, while TBX1 was expressed in the dorsal domain of the pouch, the
staining intensity was greatly reduced when compared to the control. Moreover, a reduction
in TBX1 staining intensity was also observed in the mesenchyme of the transgenic mutant
mouse model. This result was quite surprising given the fact that we were observing noncell autonomous effects when the miR-17-92 cluster was being overexpressed in the ventral
domain of the pouch. It has been reported that miR-17-92 functions in both non-cell
autonomous and cell autonomous manners, however its mode of action is highly dependent
on the type of cell it is expressed in (166). Specifically, during tumorigenesis, miR-17-92
functions in a non-call autonomous manner to promote angiogenesis (167). However, it
functions in a cell autonomous manner to promote the proliferation and inhibit the
differentiation of cancerous lung cells (168, 169). Although a role for miR-17-92 in 3rd pp
development and thymus organogenesis has never been reported, it is quite possible that in
our model system, miR-17-92 acts in a non-cell autonomous manner to regulate Tbx1
expression. Given that miRNAs can be transferred between cells in exosomes (reviewed in
(170)), non-cell autonomous miR-17-92-mediated regulation of Tbx1 may occur as a result
of this mechanism. Therefore, these data strongly suggest that miR-17-92 may act in a noncell autonomous manner within the 3rd pp endoderm to downregulate TBX1.
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CHAPTER 5: Additional mechanisms regulate TBX1 in the 3rd pp endoderm

INTRODUCTION
Complex and dynamic signaling pathways are required to commit 3rd pp progenitors
to a thymus fate and to regulate subsequent stages of TEC development. We previously
showed that ectopic expression of Tbx1 in thymus-fated cells inhibits TEC differentiation,
resulting in extremely hypoplastic fetal thymus lobes that contain an accumulation of
potentially bipotent TEC progenitors (111). These results led to the model in Figure 4
proposing that TBX1 is a key transcription factor regulating thymus development. We then
focused on identifying factors that regulate Tbx1 expression. This effort led to the discovery
that miR-17-92 regulates Tbx1 in the 3rd pp endoderm and that deletion of miR-17-92,
impairs thymus organogenesis as predicted by our model (Fig. 4). However, we noted that
deletion of miR-17-92 did not expand the TBX1 expression domain as dramatically as was
seen in the Foxn1Cre/+;R26iTbx1/+ mouse model. Moreover, using a miR-17-92 transgenic
model, we noted that miR-17-92 non-cell autonomously regulates TBX1 expression in the
dorsal endoderm and mesenchyme. These data suggest that additional mechanisms must
be in place to regulate Tbx1 expression in the 3rd pp endoderm.
To further investigate the cellular and molecular mechanisms that regulate Tbx1
expression, we have analyzed two additional mouse models that may provide clues to
identifying factors that regulate 3rd pp patterning and thymus development. Using a model in
which NCC migration is arrested (Pax3Sp/Sp) as well as a model in which Fgf8 is inserted into
the Tbx1 allele (Tbx1FGF8), we observed an increase in the Foxn1 expressing thymus-fated
domain at the expense of the Gcm2 expressing PT-fated domain. This phenotype is
diametrically opposed to the phenotype we found in the Foxn1Cre/+;R26iTbx1/+ and miR-17-92
deletion models. Therefore, the studies described in this Chapter were performed to test the
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hypothesis that NCCs and/or Fgf8 play a role in regulating Tbx1 expression as proposed in
Figure 4.
Splotch mice
Epithelial-mesenchymal interactions are essential for proper development of the
thymic primordium. NCCs migrate ventrally from the dorsal neural tube and surround the 3rd
pp. The migration, proliferation and survival of NCCs are dependent upon the transcription
factor, Pax3 (67-69). Specifically, a homozygous point mutation in the Pax3 gene (Splotch),
results in embryonic lethality by E13.5 due to numerous developmental defects (70).
Although originally characterized as athymic, our lab showed that Pax3Sp/Sp mutants have
ectopic, hyperplastic thymic lobes as compared to control littermates (18). Furthermore,
when 3rd pp patterning was investigated at E11.5, there was an expansion of the Foxn1
expressing domain and a significant reduction in the Gcm2 expressing domain suggesting
that NCCs play a role in patterning the 3rd pp. We used Splotch mice to test the hypothesis
that NCCs mediate their effect on 3rd pp patterning by inhibiting TBX1 expression.
Tbx1Fgf8 mice
As discussed in Chapter 1, BMP and FGF signaling between the pharyngeal
endoderm and mesenchyme is critical for proper development of the 3rd pp. BMP4
promotes thymus organogenesis and is expressed in the 3rd pp endoderm and surrounding
mesenchyme at E11.5, while Fgf8 is expressed in the endoderm at E10.5, but minimally
expressed, if at all, in the 3rd pp by E11.5. The expression pattern and timing of these
factors in organogenesis suggests that BMP and FGF signaling may act in a linear or
parallel pathway. During chick development, FGF8 signaling from the endoderm is
hypothesized to induce the sequential BMP4-FGF10 signaling cascade that is necessary for
thymus fate specification and Foxn1 expression in the avian 3rd and 4th pps (85). A similar
pathway may influence patterning as well as thymus fate acquisition in the mammalian 3rd
pp. We used a knock-in model in which a Tbx1 null allele drives Fgf8 expression in the
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Tbx1 domain to test the hypothesis that enforced ectopic expression of Fgf8 in the dorsal 3rd
pp prevents or reverses PT fate and expands thymus fate.

RESULTS

TBX1 expression is reduced and FOXG1 expression is expanded in the 3rd pp of E10.5
Pax3Sp/Sp mutants
We previously reported that the NCC deficiency in Splotch (Pax3Sp/Sp) mice alters 3rd
pp patterning such that the Foxn1 domain is expanded and the Gcm2 domain is reduced
(70). In a subsequent investigation, we found that Tbx1 antagonizes FOXN1 expression in
the 3rd pp (111). Therefore, we hypothesized that a deficiency in NCCs would reduce TBX1
expression and thus contribute to the expanded Foxn1 expressing domain seen in the
Pax3Sp/Sp 3rd pp. To test this premise, Pax3Sp/Sp embryos and littermate controls were
harvested at E10.5 and sectioned throughout to analyze pouch patterning using thymusand PT-region specific markers. The frequency of TBX1 positive cells appeared to be lower
in the mutant endoderm (Fig.24A,B). However, TBX1 expression was not diminished in the
mesodermal mesenchyme surrounding the mutant 3rd pp, therefore suggesting that NCCs
play a role in initiating and/or maintaining Tbx1 expression in the ventral 3rd pp endoderm.
To determine if thymus fate was already expanded in the Splotch 3rd pp by E10.5, we
stained for FOXG1, a transcription factor that is required for thymus development and is
expressed independently of, and prior to, FOXN1 in the 3rd pp (108, 111). FOXG1 was
detected in the ventral tip and proximal dorsal regions of the control 3rd pp at E10.5
(Fig.24C). However, in the Pax3Sp/Sp 3rd pp FOXG1 expression extended throughout the
ventral region and into the dorsal domain (Fig.24D). Interestingly, the expression pattern of
FOXG1 at
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Figure 24. Thymus fate is expanded in the Pax3Sp/Sp 3rd pp endoderm.
(A-D) Representative IHC stains of sagittal sections from the 3rd pp of Pax3Sp/Sp and
control E10.5 embryos. (A, B) A deficiency in NCC migration reduces the frequency of
TBX1 positive cells in the 3rd pp of Pax3Sp/Sp mutant embryos when compared to control
(red). (C-D) FOXG1 (red) is expressed in the ventral tip and proximal dorsal regions of the
control 3rd pp, but is expanded throughout the ventral domain of the Pax3Sp/Sp 3rd pp. (A-D)
EpCAM expression is reflected in green. v, ventral. d, dorsal. Scale Bars: 50 µm.

119

Figure 24. Thymus fate is expanded in the Pax3Sp/Sp 3rd pp endoderm.
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E10.5 is strikingly similar to that of FOXN1 at E11.5, as described by Griffith et al. (70) and
suggests that the NCC deficiency in Splotch embryos expands the thymus fated domain as
early as E10.5.
If thymus fate is expanded, then we would expect a reduction in PT-fated cells.
Griffith et al. reported that at E10.5, Gcm2 expression, detected by ISH, was similar in the
mutant and wildtype 3rd pp. However, our preliminary IHC data suggest that there are fewer
GCM2 positive cells in the mutant E11.5 3rd pp (Fig.25). If confirmed, the discrepancy
between the current data and the previous ISH results may be due to differences in
methodology (i.e. ISH versus IHC). It is possible that the ISH analysis was not sensitive
enough to discern a subtle distinction in Gcm2 expression or that the ISH analysis was
performed on an insufficient number 3rd pp sections. Another possibility is that the NCC
migration defect may be somewhat variable in different embryos requiring analysis of the
extent of the NCC defect in addition to analysis of pouch phenotype to determine if there is a
causal association of these parameters. In support of this notion, we observed that the size
of the white belly spot in Pax3Sp/+ adults is quite variable possibly due to differences in
frequency and/or migration of NCCs in individual mutant mice. Finally, it should be noted
that the ISH analysis of Gcm2 was performed at E10.5, whereas the IHC staining for GCM2
was performed at E11.5. There could be a reduction in Gcm2 expression between E10.5
and E11.5.
Additional studies are needed to confirm the initial observations on FOXG1 and
TBX1 expression and to resolve the apparent discrepancy in GCM2 expression.
Nevertheless, the finding that TBX1 expressing cells are reduced at E10.5 in the Pax3Sp/Sp
3rd pp coupled with the expansion of FOXG1 expressing cells into the dorsal domain
supports the hypothesis that cross-talk between pouch endoderm and NCCs plays a role in
modulating Tbx1 expression.
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Figure 25. Reduced frequency of GCM2 positive cells within the Pax3Sp/Sp 3rd pp
endoderm.
(A-B) Representative IHC stains of sagittal sections from the 3rd pp of Pax3Sp/Sp and
control E11.5 embryos. (A, B) A deficiency in NCC migration potentially reduces the
frequency of PT-fated GCM2 positive cells in Pax3Sp/S mutant embryos when compared to
control (red). EpCAM expression id reflected in green. v, ventral. d, dorsal. Scale Bars: 50
µm.
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Figure 25. Reduced frequency of GCM2 positive cells within the Pax3Sp/Sp 3rd pp
endoderm.
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Fgf8 expression is enhanced and sustained in the 3rd pp endoderm of Pax3Sp/Sp
mutants
Given that Fgf8 is required for development of pharyngeal arch derivatives and NCC
migration (78, 79), we analyzed its expression in the 3rd pp endoderm of NC-deficient
Pax3Sp/Sp embryos. At E10.5, Fgf8 is expressed in the ventral domain of the wildtype 3rd pp,
whereas in the mutant, its expression is considerably upregulated and is also detected in the
mesenchyme adjacent to the ventral domain (Fig.26A,B). By E11.5, Fgf8 is minimally
expressed, if at all, within the developing 3rd pp endoderm of the control (Fig.26C).
However, not only was Fgf8 expressed in the Pax3Sp/Sp 3rd pp, its expression was also
detected in the dorsal domain (Fig.26D). The sustained expression of Fgf8 is particularly
interesting in consideration of our previous report showing that the FOXN1-GCM2
expression boundary is shifted to expand the thymus fated domain in the Pax3Sp/Sp 3rd pp.
Moreover, these data are consistent with the notion that Fgf8 signaling promotes thymus cell
fate (85).

Bmp4 expression is enhanced in the 3rd pp endoderm of Pax3Sp/Sp mutants
Our model predicts that Fgf8 and Bmp4 interact to pattern the 3rd pp endoderm and
promote thymus cell fate. Therefore, we asked whether similar to Foxn1 and FOXG1, Bmp4
expression was expanded in the NC-deficient Pax3Sp/Sp 3rd pp. At E10.5, Bmp4 is expressed
in the ventral endoderm and mesenchyme of the control (Fig.27A). Bmp4 staining intensity
was dramatically increased in the ventral domain of the mutant 3rd pouch and its expression
extended towards the dorsal domain in a gradient-like fashion (Fig.27B). Furthermore, the
staining intensity of the Bmp4 morphogen was also greatly increased in the mutant
mesenchyme (Fig.27B).
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Figure 26. Fgf8 is ectopically expressed at E11.5 in the 3rd pp endoderm of Pax3Sp/Sp
mutants.
(A-D) ISH analysis of Fgf8 expression in the 3rd pp endoderm of Pax3Sp/Sp and
control embryos at (A,B) E10.5 and (C,D) E11.5. Note the increased expression of Fgf8 at
E10.5 in the mutant 3rd pp and its continued expression at E11.5. v, ventral. d, dorsal.
Scale Bars: 50 µm.

125

Figure 26. Fgf8 is ectopically expressed at E11.5 in the 3rd pp endoderm of Pax3Sp/Sp
mutants.
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Figure 27. Bmp4 expression is enhanced in the 3rd pp endoderm of Pax3Sp/Sp mutants.
(A,B) ISH analysis of Bmp4 expression in the 3rd pp endoderm of Pax3Sp/Sp and
control embryos at E10.5. Note the increased expression of Bmp4 in the endoderm and
mesenchyme of the mutant 3rd pp. v, ventral. d, dorsal. Scale Bars: 50 µm.

Figure 27. Bmp4 expression is enhanced in the 3rd pp endoderm of Pax3Sp/Sp mutants.
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Taken together, these analyses support the premise that NCCs play a role in
patterning the 3rd pp by promoting and/or sustaining TBX1 expression as well as by
suppressing Fgf8 and Bmp4 expression. We have modified our working model to reflect this
hypothesis.

Enforced expression of Fgf8 from the Tbx1 allele promotes FOXN1 expression
Given our data showing that expansion of the thymus fated domain in the Pax3Sp/Sp
3rd pp is associated with increased Fgf8 and Bmp4 expression as well as the recent report
showing that Fgf8 acts in a linear fashion with Bmp4 to pattern 3rd pp endoderm in the chick
(85), we asked whether enforced expression of Fgf8 in the PT-fated domain would decrease
specification of 3rd pp cells to a PT fate and conversely increase the frequency of thymus
fated cells. To answer this question, we used mice in which Fgf8 is inserted into a null Tbx1
allele (Tbx1Fgf8). Since Tbx1 is expressed as early as E7.5, we would expect Fgf8 to be
ectopically expressed early in 3rd pp patterning, and therefore test the above hypothesis.
Fgf8 insertion into both Tbx1 alleles (Tbx1Fgf8/Fgf8) is embryonic lethal and in the absence of
Tbx1 expression, the 3rd pp does not form. Therefore, we analyzed mice in which there is
only one copy of the Tbx1Fgf8 allele.
Tbx1Fgf8/+ and control littermates were harvested at E11.5 for ISH analysis of Foxn1
and Gcm2 in the 3rd pp. As expected, expression of both Foxn1 and Gcm2 mRNA was
restricted to their respective domains in the control 3rd pp endoderm (Fig.28A,C). However,
Foxn1 was expressed throughout almost the entirety of the 3rd pp in the Tbx1Fgf8/+ mutant
(Fig.28B). Furthermore, Gcm2 expression was reduced and restricted to the dorsal tip of
the mutant pouch (Fig.28D). Additionally, we noted that in some sections of the mutant
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Figure 28. Enforced expression of Fgf8 from the Tbx1 allele promotes Foxn1
expression.
(A-D) ISH analysis of (A,B) Foxn1 and (C,D) Gcm2 expression in the 3rd pp
endoderm of Tbx1Fgf8/+ and control embryos at E11.5. Note the expansion of Foxn1 at the
expense of Gcm2 within the mutant 3rd pp. Arrows indicate examples of detectable
Foxn1/Gcm2 mRNA. v, ventral. d, dorsal. Scale Bars: 50 µm.

130

Figure 28. Enforced expression of Fgf8 from the Tbx1 allele promotes Foxn1
expression.
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pouch, no Gcm2 expression was detected as Foxn1 was expressed throughout the pouch
(data not shown). Taken together, these data strongly suggest that Fgf8 expression is
antagonistic to PT cell fate establishment and promotes thymus cell fate when ectopically
expressed in the dorsal domain of the 3rd pp endoderm.

Enforced expression of Fgf8 from the Tbx1 allele promotes thymus cell fate at the
expense of PT fate
To determine if ectopic expression of Fgf8 in the PT-fated domain also reduced
TBX1 expression, we performed IHC analyses on the E11.5 3rd pp. Compared to the control,
TBX1 expression was greatly reduced in the Tbx1Fgf8/+ 3rd pp (Fig.29A,B). The frequency
and location of the TBX1 positive cells was similar to that of Gcm2 expression analyzed by
ISH. Furthermore, FOXN1 expression was detected throughout the ventral region of the
mutant pouch and extended well into the dorsal domain (Fig.29B). However, FOXN1 was
not co-expressed with the few TBX1 positive cells present in the mutant pouch. Interestingly,
the expression pattern of GCM2 was congruent with the ISH data as well as TBX1
expression (Fig.29C,D). In the control, FOXG1 expression overlapped with that of FOXN1
and was restricted to the ventral domain of the pouch (Fig.29E). Similarly, FOXG1
expression was congruent with that of FOXN1 in the mutant and expanded into the dorsal
domain of the mutant 3rd pp (Fig.29F). Taken together, these data support the notion that
Fgf8 promotes thymus fate in 3rd pp endoderm.
Additionally, it is important to note that the 3rd pp of the mutant embryo appeared
larger than that of the control (Fig.29). Although cell counts will need to be obtained to
confirm this finding, this result also suggests that ectopic, endodermal Fgf8 expression may
influence the size of the 3rd pp.
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Figure 29. Enforced expression of Fgf8 from the Tbx1 allele promotes thymus cell
fate at the expense of PT fate.
(A-F) Representative IHC stains of sagittal sections from 3rd pp of Tbx1Fgf8/+ and
control E11.5 embryos. (A, B) Ectopic expression of Fgf8 reduces the frequency of TBX1
positive cells (red) in the 3rd pp of Tbx1Fgf8/+ mutant embryos when compared to control.
(C, D) Serial sections show a concomitant reduction in the frequency of GCM2 positive cells
(red) in the 3rd pp of Tbx1Fgf8/+ mutant embryos when compared to control. (E,F) FOXG1
(red) expression is expanded throughout the ventral and into the dorsal domain of Tbx1Fgf8/+
3rd pp and is co-expressed with FOXN1 (green). (A-F) Note the expansion in the FOXN1
expression domain of the mutant 3rd pp when compared to the control. v, ventral. d, dorsal.
Scale Bars: 50 µm.
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Figure 29. Enforced expression of Fgf8 from the Tbx1 allele promotes thymus cell
fate at the expense of PT fate.

134

CONCLUSIONS
The data presented in this Chapter confirm that a deficiency of NCCs expands the
thymus-fated domain of the 3rd pp at the expense of the PT-fated domain. We also show for
the first time that ectopic expression of Fgf8 in the dorsal domain results in a similar
phenotype. These results contribute additional insight into the molecular pathways that
establish thymus fate and/or promote thymus organogenesis and are reflected in our
working model. Interestingly, the phenotype in these two models is in stark contrast to the
3rd pp phenotypes reported in the Foxn1Cre/+;R26iTbx1/+ and miR-17-92 deletion models
(Chapters 3 and 4), in which there is a reduction in FOXN1 positive cells in the 3rd pp and
aberrant thymus organogenesis.

Tbx1 expression is reduced and thymus cell fate expands in 3rd pp of NCC deficient
Pax3Sp/Sp embryos
Previous work from our lab has shown that the 3rd pp is aberrantly patterned and
thymus cell fate is expanded in the absence of NCCs at E11.5 (70). However, the
expression of Tbx1 was not analyzed in the developing endoderm of the Pax3Sp/Sp embryo.
The current investigation shows that TBX1 positive cells are reduced and FOXG1 positive
cells are expanded in the Splotch 3rd pp at E10.5. This result suggests that NCC-derived
signals may affect the establishment of organ fate boundaries by positively regulating Tbx1
expression, which in turn suppresses thymus fate and promotes PT fate in 3rd pp
progenitors. This scenario is consistent with our working model (Fig.4).
The reduction in TBX1 and expansion of FOXG1 expressing cells in the E10.5
Pax3Sp/Sp 3rd pp could be due either to altered fate commitment of endodermal progenitors or
to reversal of PT-specified cell fate. Although there may be a reduction in GCM2 positive
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cells in the E11.5 mutant pouch, the analysis of GCM2 does not resolve this issue since a
number of these cells are readily detectable. Therefore, it will be necessary to repeat these
experiments and quantify the number and frequency of GCM2 positive cells. Moreover, it
will be interesting to determine whether the GCM2 positive cells in the mutant pouch coexpress FOXG1 or FOXN1.
Fgf8 is a morphogen that contributes to cell fate in several tissues (171, 172). Our
data suggests that NC-derived signals play an essential role in limiting Fgf8 expression in
the 3rd pp. The fact that Fgf8 expression is increased in the Pax3Sp/Sp 3rd pp at E10.5 and
sustained at E11.5 has interesting implications for thymus fate specification and the
potential relationship between Fgf8 and Tbx1 expression. A recent study of 3rd pp patterning
in the chick suggested that Fgf8 might be a key factor in establishing thymus fate given its
temporal and spatial expression pattern in the developing 3rd and 4th pharyngeal pouches.
In this regard, it is interesting that Fgf8 is highly expressed in the ventral tip of the wildtype
3rd pp. This is the region where Foxn1 is first expressed. Moreover, the ventral most region
of the 3rd pp is relatively refractory to down-regulation of FOXN1 expression mediated by
ectopic Tbx1 expression in our Foxn1Cre/+;R26iTbx1/+ mutants. Therefore, high levels of Fgf8 in
3rd pp progenitors may be sufficient to establish or even reverse organ fate. Furthermore,
Fgf8 may mediate its effect on 3rd pp patterning, at least in part, by suppressing TBX1
expression. Indeed, the analysis of TBX1 expression in the Tbx1Fgf8/+ 3rd pp supports this
notion. Alternatively or in addition, TBX1 may regulate FGF8 expression. Interestingly, Fgf8
has been reported as a downstream mediator of Tbx1 function to pattern the aortic arch
(163).
Bmp4 is another morphogen that contributes to the patterning of the 3rd pp
endoderm. We have shown that its expression is significantly increased in the absence of
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NCCs at E10.5. This suggests that Bmp4 is independent of NC-derived signals and that
similar to Fgf8, NCCs may be required to dampen its expression to allow for PT fate
establishment. As seen in the Fgf8 model, Bmp4 was highly upregulated in the ventral tip of
the mutant pouch. This suggests that Bmp4 signaling may serve as a protective mechanism
against Foxn1 downregulation, thus establishing or maintaining thymus cell fate in the 3rd
pouch. Furthermore, Fgf8 has been proposed to act upstream of a Bmp4 signaling cascade
that is required for Foxn1 expression in the chick 3rd and 4th pps. While our results cannot
confirm that Fgf8 is acting upstream of Bmp4, their similar expression patterns do suggest
that Fgf8 and Bmp4 interact to promote thymus cell fate.

Enforced expression of Fgf8 in the PT domain promotes thymus cell fate at the expense of
PT fate
Fgf8 is hypothesized to initiate the BMP4-FGF10 signlaing cascade necessary for
the establishment of thymus cell fate in the chick (85). It stands to reason that in our model
system, Fgf8 may function in a similar way given its expression pattern during development.
Fgf8 is first expressed in the wildtype embryos at E6.5 during gastrulation (79) and appears
in the 3rd pp at E9.0, is downregulated by E10.5 and is almost absent form the pouch by
E11.5 (79, 86, 173). This suggests that the role of Fgf8 in patterning the 3rd pp occurs early
in development and prior to the establishment of cell fate boundaries. Our data support this
hypothesis as ectopic and sustained expression of Fgf8 promotes thymus cell fate at the
expense of PT fate. Specifically, TBX1 expression is attenuated and both FOXN1 and
FOXG1 expression domains are substantially expanded throughout almost the entirety of
the Tbx1Fgf8/+ 3rd pp.
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Similar to what was seen in the Pax3Sp/Sp mutants, the reduction in PT-fated cells (as
reflected by reduced TBX1 and GCM2) and expansion in thymus fate (as reflected by
increased FOXN1 and FOXG1) may be due to a reversion in PT fate to thymus fate, or to
alterations in initial fate commitment. Given that Fgf8 is expressed throughout the
pharyngeal endoderm, it is possible that commitment to the PT lineage never occurred.
However, given that GCM2 was expressed in the dorsal tip of the 3rd pp suggests that there
are mechanisms in place to impart irreversible PT cell fate commitment and prevent Fgf8
from downregulating TBX1 and otherwise interfering with PT fate.
Finally, it is important to emphasize that the data from analysis of 3rd pp patternng in
Tbx1Fgf8/+ mutants coincide with the results generated using the Pax3Sp/Sp mutants. We
demonstrated that a paucity of NCCs results in sustained Fgf8 expression, reduced TBX1
and expanded FOXN1 expression domains prior to E11.5. This suggests that NCCs not
only positively regulate TBX1 expression and negatively regulate Fgf8, but are also
necessary to preserve 3rd pp patterning and more importantly, PT cell fate possibly through
the regulation of Fgf8. Given that endodermal-mesenchymal crosstalk is required for
patterning the 3rd pp, this hypothesis is quite plausible.
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CHAPTER 6: Discussion
Thymus involution occurs due to the loss of TECs in aging individuals, and this
process is accelerated in patients undergoing cytoablative therapies. As a result, the
involuted thymus is no longer able to support T cell development, thus restricting the
diversity of the TCR repertoire. Consequently, cancer patients as well as aging non-patients
are not capable of mounting robust immune responses towards vaccines, cancers or newly
encountered infections. Therefore, preventing thymus involution and maintaining naive T cell
output would greatly improve overall health and wellbeing. In order to facilitate the
development of therapeutic strategies that will prevent or reverse thymus involution, the aim
of this dissertation is to identify the genetic pathways necessary to specify endodermal
progenitors to a thymus fate and maintain TEC differentiation.
By using LOF and GOF mouse models to study the potential role of transcriptional
regulators of thymus organogenesis, we have defined three significant pathways that
contribute to thymus fate specification within the 3rd pp endoderm. First, we have
demonstrated Tbx1 is antagonistic to FOXN1 expression and must be downregulated for
proper thymus organogenesis to occur. Secondly, we have shown that miR-17-92 may
function to regulate Tbx1 in both cell-autonomous and non-cell autonomous manners during
3rd pp patterning. Finally, we found that Tbx1 expression, and thus 3rd pp patterning, are
dependent upon NCC and Fgf8 regulation. Together, these data suggest that Tbx1 is a
master regulator of 3rd pp patterning and multiple mechanisms must be in place to regulate
its expression in order for thymus development to occur. Furthermore, we have
incorporated these findings into a current working model that describes the temporal and
spatial regulation of Tbx1 and the molecular mechanisms necessary for the establishment of
thymus fate (Fig.30).
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Figure 30. Model of molecular pathways that establish thymus cell fate in the 3rd pp
endoderm.
Model system of molecular signaling networks necessary for 3rd pp patterning and
thymus cell fate, adjusted to incorporate the role of NCCs. Bold lines indicate those
pathways that are discussed and tested in this dissertation.
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Figure 30. Model of molecular pathways that establish thymus cell fate in the 3rd pp
endoderm.
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Tbx1 indirectly regulates Foxn1 expression in the 3rd pp endoderm
Since loss or haploinsufficency of Tbx1 has been reported to cause thymus aplasia
or hypoplasia (114-116), it has been generally accepted that Tbx1 plays an indispensible
role in thymus organogenesis. However, the underlying reason for this thymus phenotype is
that Tbx1 is required for segmentation of the pharyngeal endoderm and in its absence 3rd pp
formation does not occur. Therefore, aberrant thymus development is secondary to defects
in 3rd pp development.
Our published data demonstrated that contrary to previous suggestions, Tbx1
expression is antagonistic to thymus development. Enforced, ectopic expression of Tbx1 in
Foxn1 positive cells resulted in an immediate downregulation of FOXN1 at E11.5. This
phenotype was unexpected as Tbx1 was not expressed in TECs until ~E11.25.
Nevertheless, by E11.5, we found a significant reduction in FOXN1 expression in the ventral
domain of the 3rd pouch. Interestingly, FOXN1 and TBX1 co-expressing cells were present
in the Foxn1Cre/+;R26iTbx1/+ 3rd pp endoderm suggesting that as soon as ectopic TBX1 is
expressed from the R26iTbx1 allele, there is a rapid downregulation of endogenous FOXN1
expression. It is likely that TBX1 regulates Foxn1 expression through an indirect
mechanism, as there is not a putative Tbx1 binding site in the Foxn1 promoter (BLAT;
UCSC Genome Bioinformatics).
Despite the ectopic expression of Tbx1, thymus cell fate was not reversed as the
Foxn1-independent markers of thymus cell fate, IL-7 and FOXG1, were expressed
throughout the ventral domain of the mutant 3rd pp. Given that thymus cell fate is
established prior to the expression of Foxn1, it is not surprising that thymus cell fate was
preserved in the mutant. The fact that thymus cell fate was not abrogated in this model is
further supported by the notion the 3rd pp cell fate is established by E9.5, as isolation and
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transplantation of the 3rd pp under the kidney capsule differentiates into a thymus (50).
Given that thymus cell fate was unaffected, these data further support the notion that cell
fate is specified prior to E10.5 and Tbx1 expression after this point is unable to alter fate
decisions within the pouch. Therefore, it would be interesting to sustain Tbx1 expression
throughout the 3rd pp endoderm beginning at E9.0.
We have performed preliminary experiments using Foxa2Cre to sustain and
ectopically express the R26iTbx1 allele throughout the pharyngeal endoderm to determine if
early, sustained expression of Tbx1 abrogates thymus cell fate. As expected, Foxa2Cre
induces TBX1 expression throughout the 3rd pp. We find a number of cells in the
Foxa2Cre;R26iTbx1 3rd pp that co-express TBX1 and FOXN1. In addition, pouch patterning is
aberrant as FOXN1 is expressed in both the ventral and dorsal domains of the 3rd pp. The
continued expression of FOXN1 despite sustained Tbx1 expression may be due to a mosaic
phenotype as using this Cre line, which has been previously reported (104). Alternatively,
mechanisms may exist to ensure endodermal commitment to the thymus lineage, despite
the presence of Tbx1. Regardless, because these FOXN1 positive cells co-express TBX1,
we hypothesize that TEC differentiation will be arrested at a progenitor stage, similar to what
was seen in our Foxn1Cre/+;R26iTbx1/+ mouse model. However, additional experiments need
to be performed to verify this initial data at E11.5 as well as to analyze fetal thymus
development.

Tbx1 is antagonistic to thymus development
Despite the significant reduction in FOXN1, the few FOXN1 positive cells in the
ventral region of Foxn1Cre/+;R26iTbx1/+ 3rd pp were able to proliferate and generate thymic
lobes. This resulted is hypoplastic fetal thymi beginning at E12.5 that persisted throughout
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ontogeny and into postnatal stages. Given that Foxn1 is required for TEC proliferation and
differentiation (57, 87, 88, 99, 143), the thymus hypoplasia may be attributable to the
significant reduction in FOXN1 expression at E11.5. Interestingly, there was a significant
accumulation of Plet-1 expressing TEC progenitors in the fetal Foxn1Cre/+;R26iTbx1/+ thymus
lobes. These cells co-expressed TBX1 and tended to localize in the subcapsular region of
the thymus, suggesting that enforced expression of ectopic TBX1 arrests TECs in a primitive
stage and prevents their differentiation. Additionally, we observed that the mutant lobes
have a larger than normal NC-derived mesenchymal capsule that persists throughout
ontogeny. Given that endodermal-mesenchymal interactions are required for pattering and
development of the 3rd pp, the persistent capsule coupled with the location of the progenitor
cells suggests that cellular crosstalk may be occurring between these two populations that
promotes a microenvironment conducive to the maintenance of TEC progenitors.

MiR-17-92 regulates Tbx1 expression in the 3rd pp endoderm
While the role of miR-17-92 has been well studied in various model systems, its
function during 3rd pp patterning and thymus development has never been defined. During
cardiac development, BMP2/4 promotes the expression of miR-17-92, which in turn binds
the 3’ UTR of Tbx1 (82, 132). This miR-mediated silencing of Tbx1 is required for
cardiomyocyte differentiation, and in its absence, the persistence of Tbx1 maintains cardiac
cells in a progenitor state (82). Interestingly, Bmp4 is a known regulator of thymus
development and our data have clearly demonstrated that Tbx1 is antagonistic to thymus
organogenesis through indirect regulation of FOXN1 (51, 81, 111). Given the striking
similarities among the transcriptional regulators during cardiac and thymus development, we
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hypothesized that a similar Bmp-miR-mediated mechanism regulated Tbx1 expression in
the developing 3rd pp to promote thymus fate or organogenesis.

MiR-17-92 is expressed in the developing 3rd pp endoderm
Using LNA probes to miR-17, miR-19a and miR-92a, we demonstrated that these
members of the miR-17-92 cluster are indeed expressed in the wildtype 3rd pp endoderm at
E10.5 and E11.5. Furthermore, we also detected their expression in the mesenchyme
surrounding the third pouch. As previously reported, Tbx1 is expressed in the 3rd pp
endoderm as well as by non-NC-derived mesenchyme (174). Since Tbx1 contains seed
sequences for miR-17-92 binding, it is not surprising that miR17-92 family members are
expressed in the mesenchyme. Notably, we found distinct expression patterns in the
endoderm and mesenchyme for each of the miRNAs that we analyzed. This may be
attributable to the fact that although co-transcribed, each member of the cluster is
differentially processed and regulated within specific tissues and at different times (175,
176). This adds an interesting complexity to miRNA regulation of mRNA given that
members of polycystronic miRNAs, such as miR-17-92, are found sequentially on the same
transcript (177). However, this suggests that each member of the miR-17-92 cluster may
serve different functions during pouch formation and its subsequent patterning.
Interestingly, we detected miR-17, miR-19a and miR-92a expression in either the ventral or
dorsal endoderm at E10.5. However, by E11.5, although expressed at different levels, each
member was detected in the ventral domain, and only moderately extended into the dorsal
domain of the 3rd pp. These results suggest that members of the miR-17-92 cluster are
functioning to downregulate Tbx1 in the ventral domain of the 3rd pp endoderm, thus
supporting our model.
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Additionally, the images of pri-miR-17-92 in the E11.5 3rd pp endoderm sent from Dr.
James Martin confirmed that the primary miR-17-92 transcript is restricted to the ventral
domain of wildtype 3rd pp at E11.5. Furthermore, these images also showed that the
polycystronic cluster is expressed in the mesenchyme. These results coincide with our data
analyzing mature members of the primary transcript. Overall, expression of miR-17-92
family members in the ventral domain of the 3rd pp is consistent with the notion that miR-1792 regulates Tbx1 expression in this region of the pouch. Taken together, these data
strongly support our hypothesis that miR-17-92 plays an important role in suppressing Tbx1
expression in the ventral domain of the 3rd pp to enable Foxn1 expression, and thus TEC
differentiation.

MiR-17-92 regulates Tbx1 expression in a non-cell autonomous manner
Global or site-specific deletion of miR-17-92 results in aberrant TBX1 expression
within the 3rd pp endoderm at E11.5. Upon global deletion of miR-17-92, TBX1 no longer
remained restricted to the dorsal domain, but rather expanded towards the ventral region of
the 3rd pouch. We also observed an increase in the mesenchymal staining intensity of TBX1
in miR-17-92Null embryos at E11.5. This observed increase in TBX1 expression in both the
endoderm and mesenchyme of mutant embryos is not surprising given that miR-17-92 has
directly binds the 3’UTR of Tbx1 (82) and our studies have shown that miR-17-92 is
expressed in both tissue types. Additionally, these data suggest that miR-17-92 may
function to regulate the abundance of Tbx1 transcript in a cell autonomous manner, as we
observed changes in the staining intensity of TBX1 in endodermal and mesenchymal cells.
Although cells expressing TBX1 were detected in the ventral domain of the miR-1792Null 3rd pp endoderm, we did not observe TBX1 positive cells in the most ventral region of
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the pouch as was seen in the Foxn1Cre/+;R26iTbx1/+ mouse model. Given that in the latter
case we were enforcing expression of Tbx1 from the strong R26 promoter in Foxn1 positive
cells, whereas in the later case we deleted only one potential regulator of Tbx1 mRNA
translation, it is not surprising that we did not see a more dramatic phenotype in the miR-1792 null 3rd pp. Furthermore, Bmp4 is expressed in the mesenchyme surrounding the ventral
tip of the 3rd pp at E10.5 and E11.5 (81), which may serve as a protective mechanism to
prevent Tbx1 from being expressed in these cells, thus ensuring that TEC differentiation will
occur in some, but not all cells within the pouch.
In contrast, site-specific deletion of miR-17-92 in TECs did not result in an expansion
of the TBX1 domain, but resulted in increased staining intensity of TBX1 in the dorsal
endoderm and throughout the mesenchyme. This phenotype is surprising given that we are
deleting miR-17-92 in the ventral domain of the 3rd pp endoderm and observing effects on
TBX1 expression within regions where no genetic manipulation is occurring. Interestingly,
miR-17-92 has been shown to act in both cell autonomous and non-cell autonomous
manners (166). In the global deletion model, miR-17-92 appears to be acting in a cell
autonomous manner to regulate Tbx1 expression in endodermal and mesenchymal tissues,
whereas in our site-specific deletion models it is acting in a non-cell autonomous manner.
We again observed miR-17-92 acting in a non-cell autonomous manner when the
cluster was overexpressed in TECs. TBX1 remained restricted to the dorsal, PT-fated
domain, but the staining intensity was greatly reduced in the Foxn1Cre/+;miR-17-92OE/+ E11.5
3rd pp. Furthermore, TBX1 expression was reduced in the mesenchyme surrounding the
mutant pouch. Interestingly, the effect on TBX1 in the mesenchyme was only detected in
mesenchymal cells adjacent to the pouch. Specifically, TBX1 expression in cells located
further away from the 3rd pp domain were unaffected by expression of the miR-17-92
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transgene in TECs and the staining intensity remained comparable to what is seen in the
control littermate. There is precedence of non-cell autonomous effects of miR-17-92. For
example, overexpression of the miR-17-92 cluster in epithelail and endothelial cells has
been shown to act in a non-cell autonomous manner to promote angiogenesis through Myc
activation (167, 178). These reports lend credence to the possibility that reduced TBX1
staining intensity in mesenchymal cells of embryos expressing a miR-17-92 transgene in
ventral 3rd pp endoderm is due to a non-cell autonomous effect.
Together the data obtained using LOF and GOF models supports our working model
in which miR-17-92 regulates Tbx1 expression in the 3rd pp endoderm. In addition, we
unexpectedly found evidence that miR-17-92 also regulates Tbx1 expression non-cell
autonomously in mesenchyme surrounding the 3rd pp.

MiR-17-92 regulation of Tbx1 promotes Foxn1 expression
Thymus and PT cell fate is first established in the most ventral and dorsal regions of
the pouch, respectively. Then as the pouch endoderm continues to proliferate particularly in
the ventral domain, thymus fate acquisition moves dorsally towards the eventual thymus-PT
boundary by E11.5 (54). At this developmental stage, there are very few, if any, cells in the
3rd pp that have not yet committed to either organ fate (50, 51, 54). However, if there are
cells present in the E11.5 3rd pp that have yet to commit to either lineage, those cells tend to
be located at the thymus and PT boundary as this is the region of the pouch that is last to
assume an organ specific fate. Interestingly, we observed cells in the E11.5 miR-17-92Null
3rd pp that did not express any of the organ-specific markers that we analyzed. Therefore,
these results suggest that in the absence of miR-17-92; 1) thymus cell fate is reversed 2)
thymus cell fate was never established or 3) these triple negative cells have assumed a
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thymus identity, but are arrested in an early progenitor state and have yet to express Foxn1.
To prove that there is a reversion in cell fate, we would need to analyze patterning before
E11.5 to determine the frequency and location of cells that express TBX1, GCM2 or
FOXG1. If cells in the ventral region express FOXG1 at E10.5 and fail to express both
thymus- and PT-specific markers at E11.5, then this would suggest a reversion in cell fate to
an endodermal progenitor. This would be a very interesting outcome given that it would
suggest that in the absence of miR-17-92, cells of the 3rd pp are extremely plastic
endodermal progenitors. However, if thymus cell fate were never established in the
absence of the miRNA cluster, we would see a persistent population of cells within the 3rd pp
endoderm from E10.5 to E11.5 that never express any marker associated with thymus cell
fate (e.g. Foxg1, Foxn1, Bmp4). The most likely outcome is that these FOXN1, TBX1 and
GCM2 negative cells within the ventral domain of the 3rd pp have assumed a thymus
identity, but are arrested and cannot differentiate. To prove this hypothesis, we will need to
analyze the miR-17-92Null 3rd pp at E10.5 and E11.5 for FOXG1 expression. Given that
FOXG1 is a Foxn1-independent predictor of thymus fate, its expression would suggest that
these cells are committed to the thymus lineage, but unable to express Foxn1 and
differentiate into TECs.
In contrast to the global deletion of miR-17-92 in the null embryos, Foxn1Cremediated deletion of the miR cluster in TECs does not occur until Foxn1 is turned on in the
ventral domain of the 3rd pp. We do not observe any triple negative cells nor do we observe
a discernable change in FOXN1 expression in the Foxn1Cre/+;miR-17-92Fl/Fl 3rd pp. This is
not surprising given that the mechanisms which regulate 3rd pp patterning remain intact until
cell fate boundaries are established. Interestingly however, we do observe cells at the
thymus and PT boundary that co-express FOXN1 and TBX1. Given that we have shown
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that Tbx1 must be downregulated to enable FOXN1 expression, co-expression of these two
transcription factors within one cell is extremely rare, thus making this finding notable. As
previously discussed, the cells located at the organ boundary are the last to assume either a
thymus or PT cell fate (50, 51, 54). This understanding coupled with the notion that miR-1792 may function in a non-cell autonomous manner suggests that miR-17-92 expression in
the ventral tip of the 3rd pp may be necessary to downregulate Tbx1 in cells at the thymusPT boundary, thus enabling these cells to express Foxn1 and differentiate into TECs.
We do not expect to see deletion of miR-17-92 in Foxn1Cre/+;miR-17-92Fl/Fl embryos
until ~E11.25 when Foxn1 is turned on in the 3rd pp endoderm. However, the frequency of
cells that co-express FOXN1 and TBX1 may be significantly increased when miR-17-92 is
deleted in 3rd pp endoderm at an earlier developmental stage, prior to cell fate-acquisition.
Using an early endoderm-specific Cre, such as Foxa2 or Sox17, will enable us to resolve
this issue. If miR-17-92 is deleted in the 3rd pp prior to cell fate commitment, it is possible
that TBX1 would be expressed throughout much of the 3rd pp endoderm and would prevent
the establishment of thymus cell fate. However, given that 1) multiple mechanisms regulate
Tbx1 expression in the 3rd pp, 2) FOXN1 is expressed in miR-17-92 global deletion mutants
and 3) our preliminary results using the Foxa2CreERt2/+;R26iTbx1/+ model showing that FOXN1
is expressed despite sustained expression of Tbx1 throughout the 3rd pp endoderm, it
seems likely that thymus fate commitment would still occur in the 3rd pp even when miR-1792 is deleted at an early stage in 3rd pp development. This outcome would further support
the notion that there are multiple mechanisms to ensure thymus cell fate.
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MiR-17-92 regulation of Tbx1 promotes thymus organogenesis
To date, we have examined thymus organogenesis in only one miR-17-92Null embryo
at E14.5. However, we observed a strikingly aberrant thymus phenotype. Despite the
paucity of FOXN1 positive cells at E11.5 in miR-17-92Null embryos, the right thymic lobe was
present in the E14.5 embryo and contained both cTECs and mTECs. However, this lobe
was hypoplastic and extremely ectopic and the left lobe was absent from the thoracic cavity.
The absence of the left lobe was an unexpected result given that both left and right 3rd pps
developed and expressed FOXN1 in E11.5 miR-17-92Null embryos. However, left-right
asymmetry has been described during thymus organogenesis (81). Specifically, the right
pouch tends to be larger and begins organ-specific migration prior to the left 3rd pp (80, 81,
162). The ectopic location of the right thymic lobe suggests that miR-17-92 may play a role
in separation from the pharyngeal endoderm and/or in the timing or execution of thymus
migration. While miR-17-92 has not been implicated in organ migration, a member of the
cluster, miR-17, has been shown to regulate lung morphogenesis through FGF10 and
STAT3 signaling (179). FGF10-mediated signaling from the NC-derived mesenchyme is
required for proper thymus development (72, 73) and NCCs promote separation and
migration of the thymus and parathyroid (62-65). Therefore, these findings may suggest a
novel role for miR-17-92 in organ migration. Interestingly, we observed a similar phenotype
in the Foxn1Cre/+;R26RiTbx1/+ mouse model. Enforced ectopic expression of Tbx1 in TECs
resulted in extremely hypoplastic fetal thymic lobes, although both lobes were present and
not ectopic. These data suggest that although reduced in frequency, the few cells that
express Foxn1 in both models are capable of proliferating and differentiating into a thymus.
They also suggest that dysregulation of Tbx1 does not completely abrogate Foxn1
expression, but is sufficient to disrupt proper thymus organogenesis.
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MiR-17-92 regulates gene expression in multiple tissues throughout development
and its importance throughout ontogeny is underscored by the fact that miR-17-92 null mice
die at birth (161). Therefore, the E11.5 3rd pp and E14.5 thymus phenotypes we observe in
miR-17-92Null embryos may be attributable to indirect effects of deleting this cluster in other
tissues, such as the mesenchyme. To address this, we site-specifically deleted miR-17-92
in TECs using Foxn1Cre. At E12.5, both thymic lobes in Foxn1Cre/+;miR-17-92Fl/Fl embryos
were comparable in size and location to those in the control. This result further supports the
notion that mesenchymal expression of miR-17-92 does plays a role in thymus migration.
Although thymus size and location in Foxn1Cre/+;miR-17-92Fl/Fl embryos was
preserved, we observed ectopic expression of TBX1 within a rare population of cells located
at the anterior-most region of the mutant thymic lobe. These cells expressed very low to
negative levels of FOXN1 and persisted until E17.5. Interestingly, these cells also
expressed the TEC progenitor marker, Plet-1. Rare TECs with the same phenotype were
also found in Foxn1Cre/+;R26iTbx1/+ thymic lobes. Clearly, enforced expression of TBX1
reduces FOXN1 expression and arrests TECs in a primitive state. Furthermore, these data
illustrate that despite the presence of TBX1, these cells are committed to the thymus, and
not PT, lineage. Similarly, in the absence of miR-17-92, cardiac progenitors are unable to
differentiate due to the persistence of Tbx1 expression (82). However, they are still
committed to the cardiomyocyte lineage. These observations suggest that Tbx1 expression
in the 3rd pp may not indicate a “default” to PT cell fate, but rather identify true endodermal
progenitors that are capable of differentiating into thymus-fated cells depending on what
signals they receive. This notion is further supported by the fact that PT cell fate, as
reflected by GCM2 expression, is unaffected when miR-17-92 is overexpressed in TECs,
despite the greatly reduced staining intensity of TBX1.
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Taken together, these results suggest a multifaceted and temporally regulated role
for Tbx1 during 3rd pp development and patterning. Specifically, Tbx1 is required early in
ontogeny for segmentation of the pharyngeal endoderm and initiation of 3rd pp patterning;
however by E10.5, its expression is required to promote PT organogenesis by interfering
with thymus organogenesis.

Fgf8, NCCs and thymus fate
We have shown that despite ectopic expression of Tbx1 or the absence of its
regulators, thymus cell fate is still established in the 3rd pp endoderm, and even though few
in numbers, the FOXN1 positive cells are able to give rise to a thymus. These models have
also demonstrated that additional mechanisms regulate Tbx1 expression in the 3rd pp and
that despite genetic manipulation, thymus cell fate may be attenuated, but it is not
abrogated.
NCCs play multiple roles in thymus organogenesis. At E10.5-E11.5, NCCs provide
signals required for appropriate patterning of 3rd pp endoderm. By E12.5, NCCs condense to
form a mesenchymal capsule around the developing thymic lobes and secrete numerous
growth factors to promote the proliferation and differentiation of TECs (64). By E14.5 NCCs
migrate into the thymic lobes to form pericytes surrounding the vascular network (66). This
dynamic role for NCC function during development is not surprising given that NCC are an
extremely plastic population of cells that give rise to numerous cell types (58).
Our previous study reported that the deficiency of NCCs in Pax3Sp/Sp embryos
resulted in a shift in the thymus-PT cell fate boundary in the E11.5 3rd pp (70). Our current
work shows that NCCs influence 3rd pp patterning even earlier. Specifically, we demonstrate
that at E10.5 the TBX1 expression domain is reduced and there is a compensatory
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expansion of FOXG1 in the 3rd pp of Pax3Sp/Sp mutants. These data could be interpreted to
suggest that NCCs are necessary to establish PT rather than thymus fate in the developing
pouch. The deficiency in NCCs in Pax3Sp/Sp mutants may prevent initial establishment or
cause reversal of PT fate. This issue may be resolved by analyzing Gcm2 expression, which
is expressed as early as E9.5. Therefore, it will be important to determine whether or not
Gcm2 expression is altered in the 3rd pp of Pax3Sp/Sp mutants.
Additionally, our work with the Pax3Sp/Sp embryos has shown that in the absence of
NCCs, Fgf8 expression is sustained and expanded in the ventral domain of the mutant 3rd
pp endoderm and surrounding mesenchyme. Furthermore, Fgf8 is thought to induce the
Bmp4 signaling cascade to necessary to establish thymus fate in the chick endoderm (85).
Interestingly, we observed a substantial increase in Bmp4 expression, similar to that of Fgf8,
in the NC-deficient model. These results strongly support a similar hypothesis in our model
system that Fgf8 is an important regulator of thymus cell fate and may function upstream of
Bmp4 to pattern the murine 3rd pp.
The analysis of 3rd pp patterning in Pax3Sp/Sp mutants suggests that NCCs are
required to sustain Tbx1 expression in the dorsal domain and extinguish Fgf8 expression in
the ventral region. Previous studies have demonstrated a genetic interaction between Tbx1
and Fgf8 (163). Indeed, we have shown that Tbx1 expression is reduced in the 3rd pp of
Tbx1Fgf8/+ embryos. The ectopic expression of Fgf8 in the dorsal domain results in a
phenotype that is strikingly similar to that of the Pax3Sp/Sp mutants. ISH analysis revealed an
expansion of Foxn1 and a reduction in Gcm2 expression.
In summary, we have shown that Tbx1 negatively regulates FOXN1 expression in
the 3rd pp endoderm and must be downregulated for TEC differentiation to occur. Through
the use of LOF and GOF mouse models, we demonstrated that miR-17-92 regulates Tbx1
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expression in the 3rd pp endoderm, potentially via both cell autonomous and non-cell
autonomous mechanisms. Interestingly, this regulation may occur as a result of Bmp2/4
promoting the endodermal expression of miR-17-92 at E10.5, which in turn binds the 3’UTR
of Tbx1 and silences its expression in the ventral domain of the 3rd pp endoderm.
Furthermore, our data suggest that NCCs play an indispensible role in patterning the 3rd pp
and are necessary to maintain PT-cell fate and Tbx1 expression. In their absence, Fgf8 and
Bmp4 expression are dramatically upregulated, resulting in the expansion of thymus fate
within the 3rd pp endoderm. Moreover, ectopic expression of Fgf8 from the Tbx1 allele
abrogates PT fate and downregulates TBX1, further supporting the notion that Fgf8 is
required for the establishment of thymus fate. Based on these data, we have modified our
initial working model to reflect the multiple mechanisms necessary to regulate Tbx1 in the 3rd
pp endoderm, and thus promote the establishment of thymus fate (Fig.30).

Future Directions
Our preliminary data strongly suggest that FOXN1 expression is maintained despite
sustained and ectopic expression of Tbx1 prior to the establishment of cell fate within the 3rd
pp. However, it is important to determine if thymus organogenesis occurs in this model, and
if so, how TEC differentiation is affected. Furthermore, the Foxa2Cre;R26iTbx1 and
Foxn1Cre;R26iTbx1 models will allow us to address how Fgf8 and Tbx1 interact to pattern the
3rd pp. Our data imply that Fgf8 negatively regulates Tbx1 in the 3rd pp. However, a key
experiment will be to determine if Fgf8 is still expressed either model. Furthermore, if Fgf8
were expressed in proximity to the few FOXN1 positive cells, this result would strongly
implicate the growth factor as an important regulator of thymus fate.
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It would also be interesting to temporally and spatially delete Fgf8 in the 3rd pp to
determine if thymus cell fate is abrogated in the absence of Fgf8. If true, this would
establish Fgf8 as a key component in 3rd pp patterning and cell fate commitment. However,
another outcome would be that FOXN1 is expressed in the absence of Fgf8. Based on our
models, this outcome is also plausible given that FOXN1 positive cells are present in the
ventral tip of the 3rd pp despite ectopic TBX1 expression. This result would bolster the
conclusion that there are mechanisms in place to ensure that thymus development does
occur. Given that Bmp4 positively regulates thymus development and it is upregulated in
the absence of NCCs, similar to Fgf8, exploring the expression pattern of Bmp4 in all of
these models will further define how these factors are interacting to pattern the 3rd pp.
We hypothesize that both Bmp4 and Fgf8 act upstream of miR-17-92. Therefore,
analyzing the expression pattern and staining intensity of the miRNA cluster in models that
express significant amounts of Bmp4 would clarify if miR-17-92 is functioning downstream of
Bmp in our model system. Another approach to address this point would be to analyze
pouch patterning, thymus development and miR-17-92 expression in Bmp2/4 compound
mutants.
Although miR-17-92 functions in both cell autonomous and non-cell autonomous
manners, its mode of action is highly dependent upon cell type (168, 169). It has been
shown that miRNAs are present in exosomes and are able to fuse with the membrane of
distant or neighboring cells through multiple mechanisms. Exosomes can interact with
receptors on the cell surface, fuse with the plasma membrane or become internalized and
either released or degraded by the cell (180-182). Therefore, it will be very interesting to
determine if a similar mechanism is occurring in our model systems.
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Taken together, the aims of this thesis have identified novel genetic pathways that are
critical in defining TEC fate, maintaining TEC differentiation and demonstrated how they can
potentially be incorporated into a regulatory network, which up until now have been elusive.
These mechanisms, as well as molecular targets of these mechanisms, can be used to
develop therapeutic strategies to generate TECs from endodermal progenitors in order to
produce a functional thymus, or regenerate an involuted thymus, which can support and
promote T cell development in vivo or in vitro. Ultimately, this will restore robust immune
responses in immunocompromised and aging, non-patients.
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